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Abstract
A randomised trial of the effect and cost-effectiveness
of early intensive multifactorial therapy on 5-year
cardiovascular outcomes in individuals with screen-detected
type 2 diabetes: the Anglo–Danish–Dutch Study of Intensive
Treatment in People with Screen-Detected Diabetes
in Primary Care (ADDITION-Europe) study
Rebecca K Simmons,1 Knut Borch-Johnsen,2,3 Torsten Lauritzen,3
Guy EHM Rutten,4 Annelli Sandbæk,3 Maureen van den Donk,4
James A Black,1 Libo Tao,1 Edward CF Wilson,5 Melanie J Davies,6
Kamlesh Khunti,6 Stephen J Sharp,1 Nicholas J Wareham1
and Simon J Griffin1*
1Medical Research Council Epidemiology Unit, School of Clinical Medicine, University of
Cambridge, Cambridge, UK
2Holbæk Hospital, Holbæk, Denmark
3School of Public Health, Department of General Practice, University of Aarhus, Aarhus, Denmark
4Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht,
the Netherlands
5Department of Public Health and Primary Care, Cambridge Centre for Health Services Research,
University of Cambridge, School of Clinical Medicine, Cambridge, UK
6Diabetes Research Centre, Leicester Diabetes Centre, University of Leicester, Leicester General
Hospital, Leicester, UK
*Corresponding author simon.griffin@mrc-epid.cam.ac.uk
Background: Intensive treatment (IT) of cardiovascular risk factors can halve mortality among people with
established type 2 diabetes but the effects of treatment earlier in the disease trajectory are uncertain.
Objective: To quantify the cost-effectiveness of intensive multifactorial treatment of screen-detected diabetes.
Design: Pragmatic, multicentre, cluster-randomised, parallel-group trial.
Setting: Three hundred and forty-three general practices in Denmark, the Netherlands, and Cambridge
and Leicester, UK.
Participants: Individuals aged 40–69 years with screen-detected diabetes.
Interventions: Screening plus routine care (RC) according to national guidelines or IT comprising
screening and promotion of target-driven intensive management (medication and promotion of healthy
lifestyles) of hyperglycaemia, blood pressure and cholesterol.
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Main outcome measures: The primary end point was a composite of first cardiovascular event
(cardiovascular mortality/morbidity, revascularisation and non-traumatic amputation) during a mean
[standard deviation (SD)] follow-up of 5.3 (1.6) years. Secondary end points were (1) all-cause mortality;
(2) microvascular outcomes (kidney function, retinopathy and peripheral neuropathy); and (3) patient-reported
outcomes (health status, well-being, quality of life, treatment satisfaction). Economic analyses estimated mean
costs (UK 2009/10 prices) and quality-adjusted life-years from an NHS perspective. We extrapolated data to
30 years using the UK Prospective Diabetes Study outcomes model [version 1.3; © Isis Innovation Ltd 2010;
see www.dtu.ox.ac.uk/outcomesmodel (accessed 27 January 2016)].
Results: We included 3055 (RC, n= 1377; IT, n= 1678) of the 3057 recruited patients [mean (SD) age
60.3 (6.9) years] in intention-to-treat analyses. Prescription of glucose-lowering, antihypertensive and
lipid-lowering medication increased in both groups, more so in the IT group than in the RC group. There
were clinically important improvements in cardiovascular risk factors in both study groups. Modest but
statistically significant differences between groups in reduction in glycated haemoglobin (HbA1c) levels,
blood pressure and cholesterol favoured the IT group. The incidence of first cardiovascular event [IT 7.2%,
13.5 per 1000 person-years; RC 8.5%, 15.9 per 1000 person-years; hazard ratio 0.83, 95% confidence
interval (CI) 0.65 to 1.05] and all-cause mortality (IT 6.2%, 11.6 per 1000 person-years; RC 6.7%, 12.5 per
1000 person-years; hazard ratio 0.91, 95% CI 0.69 to 1.21) did not differ between groups. At 5 years,
albuminuria was present in 22.7% and 24.4% of participants in the IT and RC groups, respectively [odds
ratio (OR) 0.87, 95% CI 0.72 to 1.07), retinopathy in 10.2% and 12.1%, respectively (OR 0.84, 95% CI
0.64 to 1.10), and neuropathy in 4.9% and 5.9% (OR 0.95, 95% CI 0.68 to 1.34), respectively.
The estimated glomerular filtration rate increased between baseline and follow-up in both groups
(IT 4.31 ml/minute; RC 6.44 ml/minute). Health status, well-being, diabetes-specific quality of life and
treatment satisfaction did not differ between the groups. The intervention cost £981 per patient and was
not cost-effective at costs ≥ £631 per patient.
Conclusions: Compared with RC, IT was associated with modest increases in prescribed treatment,
reduced levels of risk factors and non-significant reductions in cardiovascular events, microvascular
complications and death over 5 years. IT did not adversely affect patient-reported outcomes. IT was not
cost-effective but might be if delivered at a reduced cost. The lower than expected event rate,
heterogeneity of intervention delivery between centres and improvements in general practice diabetes care
limited the achievable differences in treatment between groups. Further follow-up to assess the legacy
effects of early IT is warranted.
Trial registration: ClinicalTrials.gov NCT00237549.
Funding details: This project was funded by the NIHR Health Technology Assessment programme and will
be published in full in Health Technology Assessment; Vol. 20, No. 64. See the NIHR Journals Library
website for further project information.
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Plain English summary
D iabetes is a common chronic condition associated with an increased risk of heart attack, stroke,amputation, eye disease and kidney damage. Many people have symptoms or a complication when
diagnosed with diabetes; however, the true onset of the disease occurs several years earlier. Although it
seems logical to propose that earlier detection would be beneficial, this has not been clearly established.
We aimed to discover whether or not intensive treatment of people who have their diabetes detected
early using preventative medication and lifestyle advice leads to health benefits at 5 years and in the
longer term.
A total of 343 general practices in England, Denmark and the Netherlands took part. Following invitation
to a screening programme, 3057 people were diagnosed with diabetes. General practices were allocated
by chance to deliver either intensive treatment (a combination of medication and advice on lifestyle
changes, e.g. diet and physical activity) or standard care according to national guidelines. After 5 years
we re-examined participants to see whether or not intensive treatment reduced the risk of diabetes-related
complications such as heart attack and stroke.
After 5 years, people receiving intensive treatment had slightly lower cholesterol levels, blood pressure and
blood glucose levels than those receiving routine care. However, we cannot be sure that the small reductions
in the number of heart attacks, strokes and premature deaths and in the level of visual impairment and
kidney damage between the groups were not due to chance. Participants in both groups reported similar
levels of well-being and quality of life and were equally satisfied with the treatment that they received.
Intensive treatment is likely to be cost-effective only if it can be delivered at a reduced cost.
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Scientific summary
Background
Type 2 diabetes represents a major global public health challenge. The UK NHS spends £7.7B per year on
the complications of diabetes, mainly attributable to macrovascular disease. Intensive treatment (IT) of
multiple cardiovascular risk factors can halve the rates of cardiovascular disease (CVD) and mortality among
people with established type 2 diabetes. The effect of intensive multifactorial treatment earlier in the
course of the disease is unknown. Resolving this uncertainty is important in assessing the costs and
benefits of screening for diabetes.
Objectives
We aimed to examine the effectiveness of intensive multifactorial treatment among patients with type 2
diabetes detected by screening for 5-year macrovascular, microvascular and patient-reported outcomes.
We also aimed to estimate the short- and long-term cost-effectiveness of IT compared with routine care
(RC) in terms of mean costs and quality-adjusted life-years (QALYs) accrued.
Methods
We undertook a pragmatic, multicentre, cluster-randomised, parallel-group trial with a concurrent
economic evaluation of intensive multifactorial treatment among individuals with screen-detected diabetes.
A total of 343 general practices in Denmark, the Netherlands, and Cambridge and Leicester, UK, were
independently randomised to screening plus RC of diabetes according to national guidelines or screening
and promotion of target-driven IT of multiple risk factors. We undertook population-based stepwise
screening among people aged 40–69 years (50–69 years in the Netherlands) without known diabetes
between April 2001 and December 2006. Individuals were diagnosed with diabetes according to 1999
World Health Organization criteria. General practitioners (GPs) assessed patients against exclusion criteria:
having an illness with a life expectancy of < 12 months; being housebound; being pregnant or lactating; or
having psychological or psychiatric problems that might invalidate informed consent.
In IT practices, GPs, practice nurses and participants were educated in target-driven management
(using medication and promotion of a healthy lifestyle) of hyperglycaemia, blood pressure and cholesterol.
The intervention delivered was practice based, except in Leicester, where patients also had access to
individualised community clinics every 2 months. Treatment targets and algorithms were based on trial
data demonstrating the benefits of IT of CVD risk factors among those with type 2 diabetes. Practitioners
were advised to treat to the following targets: glycated haemoglobin (HbA1c) of < 53mmol/l (7.0%) if
HbA1c > 6.5%; blood pressure of ≤ 135/85mmHg if ≥ 120/80mmHg; cholesterol of < 5mmol/l without
ischaemic heart disease or < 4.5mmol/l with ischaemic heart disease; and prescription of aspirin to those
treated with antihypertensive medication. The treatment algorithm included a recommendation to
prescribe a statin to all patients with a cholesterol level of ≥ 3.5mmol/l following results from the Heart
Protection Study. Individuals in the RC group received the standard pattern of diabetes care according to
current recommendations in each centre. Group allocation was concealed from those assessing and
adjudicating outcomes.
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The primary end point was a composite of first cardiovascular event, including cardiovascular mortality,
cardiovascular morbidity (non-fatal myocardial infarction and non-fatal stroke), revascularisation and
non-traumatic amputation during a mean [standard deviation (SD)] follow-up of 5.3 (1.6) years. In each
centre participants’ medical records or national registers were searched for potential end points. For each
possible end point, packs containing relevant clinical information were prepared and sent to two members
of the expert committees, who were unaware of group allocation, for independent adjudication according
to an agreed protocol using standardised case report forms.
Secondary end points were (1) all-cause mortality; (2) microvascular outcomes, including kidney function
[microalbuminuria, macroalbuminuria and estimated glomerular filtration rate (eGFR)], retinopathy (retinal
photos) and peripheral neuropathy (questionnaire data) at 5 years; and (3) patient-reported outcomes,
including health status (European Quality of Life-5 Dimensions) at baseline and 5 years and health status
[Short Form questionnaire-36 items (SF-36), European Quality of Life visual analogue scale (EQ-VAS)],
well-being (12-item short form of the Well-Being Questionnaire), diabetes-specific quality of life (Audit of
Diabetes-Dependent Quality of Life) and satisfaction with diabetes treatment (Diabetes Treatment
Satisfaction Questionnaire) at 5 years.
An individually randomised trial would have required a total of 2700 individuals (1350 per group) to detect
a 30% reduction in cumulative risk of the primary end point at a 5% significance level and with 90%
power, allowing for 10% loss to follow-up and assuming an event rate in the RC group of 3% per year
[based on results from the UK Prospective Diabetes Study (UKPDS)]. We expected a minimal effect of
clustering within general practices, with an estimated intracluster correlation coefficient of 0.01; assuming
an average of 10 participants per general practice, the design effect was 1.09 and thus we inflated the
estimated sample size for this cluster trial to 3000.
An economic evaluation of the intervention in the UK was undertaken from a UK payer (NHS) perspective
using trial data to estimate the mean costs and QALYs gained per patient for the IT and RC interventions.
We report short-term (within-trial) and long-term (10–30 years based on decision modelling) incremental
cost-effectiveness ratios (ICERs) and associated decision uncertainty.
Results
We recruited 3057 (RC, n= 1379; IT, n= 1678) participants between 2001 and 2006. Two participants
from the RC group withdrew consent in the first few months of the study and hence data were included
for 1377 RC participants. Prescription of glucose-lowering, antihypertensive and lipid-lowering medication
increased in both groups, with more patients in the IT group than in the RC group prescribed
cardioprotective medication at follow-up. Clinically important improvements in cardiovascular risk factors
and modelled cardiovascular risk were observed in both study groups between baseline and 5 years’
follow-up. Modest differences between groups in the reduction in levels of HbA1c, blood pressure,
cholesterol and modelled cardiovascular risk favoured the IT group. In the whole trial cohort, 10-year
modelled CVD risk was 27.3% (SD 13.9%) at baseline and 21.3% (SD 13.8%) at 5 years’ follow-up. The
incidence of first cardiovascular event [IT 7.2%, 13.5 per 1000 person-years; RC 8.5%, 15.9 per 1000
person-years; hazard ratio 0.83, 95% confidence interval (CI) 0.65 to 1.05] and all-cause mortality
(IT 6.2%, 11.6 per 1000 person-years; RC 6.7%, 12.5 per 1000 person-years; hazard ratio 0.91,
95% CI 0.69 to 1.21) did not differ significantly between groups.
Five years after diagnosis any kind of albuminuria was present in 22.7% of participants in the IT group and
24.4% of participants in the RC group [odds ratio (OR) 0.88, 95% CI 0.72 to 1.07). Retinopathy was
present in 10.2% of the IT group and 12.1% of the RC group (OR 0.84, 95% CI 0.64 to 1.10); eight
patients had severe retinopathy (n= 1 IT; n= 7 RC). Neuropathy was present in 4.9% and 5.9% of the IT
and RC groups, respectively (OR 0.95, 95% CI 0.68 to 1.34). The eGFR increased between baseline and
follow-up in both groups (IT 4.31 ml/minute; RC 6.44 ml/minute).
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Health status, well-being, diabetes-specific quality of life and treatment satisfaction did not differ
significantly between the IT group and the RC group after 5 years’ follow-up. There was some
heterogeneity between centres [I2 between 13% (SF-36 physical functioning) and 73% (EQ-VAS)].
The incremental cost to the NHS of the IT intervention was £285, £935, £1190 and £1745 over a 1-, 5-,
10- and 30-year time horizon, respectively (discounted at 3.5%). Incremental QALYs were 0.0000,
–0.0040, 0.0140 and 0.0465 over the same time horizons. Point estimate ICERs suggested that the
intervention was not cost-effective although the ratio improved over time: the ICER over 10 years was
£82,250, falling to £37,500 over 30 years. The ICER fell below £30,000 only when the intervention cost
was below £631 per patient; we estimated the cost of the intervention at £981.
Conclusions
Compared with RC, IT was associated with modest increases in prescribed treatment and reduced levels of
cardiovascular risk factors, but reductions in the incidence of cardiovascular events, microvascular
complications and death over 5 years were not statistically significant. Despite increasing age and diabetes
duration there was a decline in modelled CVD risk in the whole trial cohort in the 5 years following
diagnosis. The IT intervention did not adversely affect patient-reported outcomes. Given conventional
thresholds for cost-effectiveness, the IT intervention was not cost-effective compared with RC for
screen-detected diabetes patients in the UK. The intervention may be cost-effective if it can be delivered at
a reduced cost.
The lower than expected CVD event rate means that the 5-year duration of follow-up may be insufficient
to detect a potential difference between groups. The apparent divergence of event rates from 4 years
suggests that further follow-up of this trial is justified to test whether or not IT reduces cardiovascular risk
in the long term as seen in the UKPDS.
Intensive treatment by lifestyle intervention and prescription of cardioprotective medication led to clinically
important reductions in CVD risk factors and modelled CVD risk in the trial cohort. Furthermore, IT was not
associated with adverse patient-reported outcomes. As such, health practitioners might consider treating
multiple cardiovascular risk factors early and intensively in the diabetes disease trajectory, when the rate of
CVD risk progression may be slowed.
Trial registration
This trial is registered as NCT00237549.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Burden of diabetes
Type 2 diabetes is a common chronic disease, which affected 382 million people worldwide in 2013.1 It is
estimated that there will be 592 million individuals living with diabetes by 2035. Diabetes is a major cause
of premature death. Global mortality attributable to known diabetes in adults aged 20–79 years in the
year 2013 is estimated at 5.1 million deaths, which is 8.4% of total world mortality.1 Diabetes is ranked
among the leading causes of blindness, renal failure and lower limb amputation in virtually every
developed society. People with diabetes have an increased risk of cardiovascular, cerebrovascular and
peripheral vascular disease (PVD) and have a reduced risk of survival after suffering from silent ischaemia
and myocardial infarction (MI) (compared with those without diabetes). Around 65% of individuals with
type 2 diabetes die of cardiovascular disease (CVD). Diabetes is a very expensive chronic condition. It
imposes a huge burden on national economies and health-care systems, as well as costs for individuals
with diabetes and their families. Expenditure related to diabetes in 2010 was estimated to be
approximately 10% of total health-care budgets in the UK and is projected to rise to 17% in 2035.2
Preventing diabetes
The high social and economic cost of diabetes makes a compelling case for prevention of the disease.
But where should governments and health services focus their attention? Most research has been
completed on the tertiary prevention of diabetes, that is, the treatment of people with established disease.
There have been significant improvements in the treatment of individuals with diabetes3 and there is good
evidence that the development of long-term complications of diabetes can be significantly decreased by
intensive treatment (IT) (see Screening and early treatment for early diabetes). We also have long-term
evidence that diabetes can be prevented among those at high risk of developing the disease (primary
prevention).4 Intensive lifestyle and pharmacological interventions reduce the rate of progression of type 2
diabetes among people with impaired glucose tolerance (IGT). In a meta-analysis of published diabetes
prevention trials, Gillies et al.4 reported pooled hazard ratios of 0.51 [95% confidence interval (CI) 0.44 to
0.60] for lifestyle interventions compared with standard advice and 0.70 (95% CI 0.62 to 0.79) for oral
diabetes drugs compared with the control. Longer-term follow-up of these trials provides evidence of the
sustained prevention of diabetes.5–7 Delaying or preventing diabetes in this way also reduces the risk of
microvascular complications and reduces cardiovascular and all-cause mortality.8,9
Secondary prevention strategies (i.e. earlier detection, e.g. by screening) have received little attention in the
past. The current evidence base for the recommendation of screening and early treatment for diabetes
is limited.
Screening and early treatment for diabetes
Type 2 diabetes meets many of the formal criteria for a disease for which screening is justified.10 The
condition is an important health problem associated with a substantial burden of suffering and health
service cost. The natural history of the disease is well characterised.11,12 The condition is frequently
asymptomatic,13 with the true onset occurring several years before diagnosis.11,14 Although detection of the
condition may be improving in some parts of the world,15 nearly half of all people with diabetes remain
undiagnosed.1 When patients are diagnosed, many already have complications, such as CVD, chronic kidney
disease and heart failure, retinopathy and neuropathy.16–18 This suggests a potential window for earlier
detection and treatment. Furthermore, there are a number of screening tests that are simple, safe and
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validated and that perform reasonably well when evaluated against recommended diagnostic criteria.19
Modelling studies suggest that a programme of screening for diabetes would reduce both all-cause and
diabetes-related mortality.20–22 However, these estimates depend on a number of key assumptions. The only
published trial of screening to date did not show an effect of population-based screening on mortality over
10 years of follow-up.23
The National Screening Committee states that there should be an effective treatment for individuals
identified through early detection, with evidence of early treatment leading to better outcomes than late
treatment.10 A screening programme for diabetes is most likely to seek to prevent CVD, the leading
cause of premature death and disability among patients with diabetes. There is good evidence that the
development of long-term complications of diabetes can be significantly decreased by IT. Results from the
UK Prospective Diabetes Study (UKPDS) and the Kumamato trials have demonstrated the benefits of tight
glycaemic24,25 and blood pressure control,26 whereas several trials, including the Collaborative Atorvastatin
Diabetes Study27 and the Heart Protection Study (HPS),28 have confirmed the benefits of lipid-lowering
drugs. The Steno study is one of the few trials to compare the benefits of targeted intensive multifactorial
treatment with those of routine care (RC) for risk factors for CVD in individuals with established diabetes.29
After 13 years of follow-up, patients receiving the IT had a 59% (95% CI 0.25% to 0.67%) lower risk of a
CVD event and a 46% (95% CI 0.32% to 0.89%) lower risk of all-cause mortality than those receiving
RC. When we started our research in 2010, there was no trial evidence that intensive multifactorial
treatment improved CVD outcomes when commenced in the lead time between detection by screening
and diagnosis in routine clinical practice.
In terms of preventing microvascular complications, treatment of individual risk factors such as blood
pressure and glucose level reduces the risk of microvascular complications among clinically diagnosed
patients.24,30–32 IT of multiple risk factors in the Steno study was associated with a 61% (95% CI 13% to
83%) lower risk of nephropathy, a 58% (95% CI 14% to 79%) lower risk of retinopathy and a 63%
(95% CI 21% to 82%) lower risk of autonomic neuropathy.33 However, the effects on microvascular
outcomes of starting multifactorial treatment earlier in the course of the disease are uncertain. Data from
trials of IT of hyperglycaemia suggest that beneficial effects can be seen for microvascular outcomes in
the short term, whereas cardiovascular benefits are evident only with longer follow-up. However, there
remains some uncertainty about the merits of tight glycaemic control.34,35
Little research has been completed on the potential effects of intensive multifactorial treatment on
patient-reported outcome measures (PROMs) early in the course of the disease. For largely asymptomatic
patients, such a treatment regime might be burdensome. Health practitioners might be reluctant to offer
IT including the prescription of several medications and recommendations to change several lifestyle
behaviours; this might lead to psychosocial stress and reduced satisfaction with treatment.36 When
assessing the effectiveness of early treatment, PROMs are a valuable complement to hard outcomes such
as mortality and cardiovascular events. They are also increasingly being used as key performance indicators
in chronic illness. PROMs reflect a patient’s assessment of his or her own health and well-being and involve
questions about physical and social functioning and mental well-being. They may include both generic and
disease-specific questions. The reliability of PROMs is similar to that of clinical measures such as blood
pressure or blood glucose monitoring.37 The use of PROMs has been recommended in the evaluation of
health-care services and in regulatory decision-making.38 Their use provides an opportunity to help drive
changes in how health care is organised and delivered.37
Evidence from the UKPDS study suggests that IT of blood pressure and blood glucose among newly
diagnosed type 2 diabetes patients is not associated with adverse effects on quality of life.39 The Action to
Control Cardiovascular Risk in Diabetes (ACCORD) trial of intensive glycaemic control in US patients with
long-standing type 2 diabetes was associated with modest improvements in satisfaction with diabetes
treatment and did not lead to an increase in health-related quality of life.40 The effects of intensive
multifactorial treatment on PROMs among people with type 2 diabetes detected by screening are
not known.
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In addition to a lack of information on the effects of intensive multifactorial intervention on macrovascular,
microvascular and PROMs early in the diabetes disease trajectory, little is known about the cost-effectiveness
of such treatment. It is expected that increasing numbers of new patients will be identified as governments
introduce national assessment programmes, such as the NHS Health Checks programme.41 The balance of
benefits, harms and costs of IT may not be the same for screen-detected individuals as for those with
clinically diagnosed and long-standing diabetes.
The ADDITION-Europe trial
In 2001 a group of colleagues from Cambridge in the UK, Utrecht in the Netherlands and Copenhagen
and Aarhus in Denmark came together to answer some of the outstanding questions about screening and
early treatment for diabetes. Colleagues in Leicester were later invited to join the collaboration. The main
aim of the Anglo–Danish–Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in
Primary Care (ADDITION-Europe) was to investigate whether or not intensive multifactorial treatment
improves outcomes compared with RC when commenced in the lead time between detection by screening
and clinical diagnosis. This was a two-phase study consisting of a screening phase and a pragmatic,
cluster-randomised, parallel-group trial. Results from the screening phase of the study have previously been
reported.42–46 This report concerns the results from the 5-year follow-up of the trial, which was funded in
the UK by the National Institute for Health Research (NIHR) Health Technology Assessment programme.
Aims
To examine the effect of intensive multifactorial treatment compared with RC on (1) cardiovascular
outcomes, (2) microvascular outcomes and (3) self-reported health status, well-being, diabetes-specific
quality of life and treatment satisfaction after 5 years’ follow-up. A further aim was to assess the
cost-effectiveness of intensive multifactorial treatment compared with RC in the UK setting.
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Chapter 2 Trial design and methods
Design
The ADDITION-Europe trial was set up to evaluate the effectiveness of intensive multifactorial treatment
with regard to macrovascular, microvascular and PROMs among individuals with screen-detected diabetes.
It consisted of two phases – a screening phase and a pragmatic cluster-randomised parallel-group trial – in
four centres (Denmark, Cambridge, UK, the Netherlands and Leicester, UK). This report concerns the results
of the treatment trial (see Chapter 3). The main trial was supplemented with an economic evaluation to
consider the cost-effectiveness of the intervention in the UK (see Chapter 4). A description of the trial
protocol has already been published.47
Ethical approval and research governance
The study was approved by local ethics committees in each centre and participants provided
informed consent.
Randomisation, concealment and blinding
Of 1312 general practices invited to participate, 379 (29%) agreed and 343 clusters (26%) were randomised.
Practices were randomly assigned by statisticians independent of the measurement teams to screening plus
routine diabetes care or screening followed by intensive multifactorial treatment in a 1 : 1 ratio. Randomisation
included stratification by county and number of full-time family physicians in Denmark and by single-handed
or group status in the Netherlands. In Cambridge, randomisation included minimisation for the local district
hospital and the number of patients per practice with diabetes. In Leicester, randomisation included
minimisation for practice demographics, deprivation status and prevalence of type 2 diabetes.
Population-based stepwise screening took place between April 2001 and December 2006 among people
aged 40–69 years (50–69 years in the Netherlands) without known diabetes, as previously described.43,48–50
Screening programmes, which varied by centre (Table 1), consisted of a risk score51 (Cambridge) or
self-completion questionnaires (Denmark52 and the Netherlands54) followed by capillary glucose testing or
an invitation to attend an oral glucose tolerance test without prior risk assessment (Leicester). Individuals
were diagnosed with diabetes according to the World Health Organization (WHO)’s 1999 criteria,56
including the requirement for confirmatory tests on separate occasions.
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TABLE 1 Characteristics of the ADDITION-Europe screening programmes, intervention delivery and outcome
ascertainment by study centre
Centre Screening programme Intervention delivery Outcome ascertainment
Cambridge,
UK
l Electronic medical records of
patients aged 40–69 years
were searched for routinely
collected information to
allow the calculation of the
Cambridge diabetes
risk score51
l Individuals with a score of
≥ 0.17 were invited by their
GP to attend a stepwise
screening programme
including capillary RBG, FBG
and HbA1c tests
l Practice-based educational
meetings with GPs and nurses
to discuss treatment targets,
algorithms and lifestyle advice
l Audit and feedback via
follow-up practice-based
meetings up to twice per year
l Practice staff were provided
with educational materials
for patients
l Small financial incentives
for GPs
l Participants were tagged for
mortality with the Office for
National Statistics
l Sensitive electronic searches
of general practice records
were undertaken between
March 2009 and February
2010. If a possible event
was highlighted copies were
made of medical records.
Additional information was
obtained from hospital
medical records and
coroners’ offices as required
Denmark (a) Patients aged 40–69 years
were sent a letter including
questions from the Danish
Diabetes Risk Score
Questionnaire52 and
advising those with a score
of ≥ 5 to arrange an
appointment with their GP
to enter a stepwise
screening programme
including capillary RBG,
FBG and HbA1c testing
(b) Patients aged 40–69 years
were asked to fill in the
Danish Diabetes Risk Score
Questionnaire52 when
attending their GP surgery.
Those at high risk entered
the same stepwise
screening programme
l Small group or practice-based
educational meetings with
GPs and nurses to discuss
treatment targets, algorithms
and lifestyle advice
l Audit and feedback included
in follow-up group meetings
up to twice a year or
co-ordinated by post
l Practice staff were provided
with educational materials
for patients
l Small financial incentives
for GPs
l Patients were sent reminders
if annual measures
were overdue
l The national patient
register was searched on
31 December 2009 for
deaths and for ICD-10 codes
for cardiovascular events
(I08–I77) and surgical
procedures concerning
amputations and
revascularisations. For
possible events, information
was obtained from hospital
medical records and
coroners’ offices as required
Leicester, UK l Patients aged 40–69 years
were invited directly for an
OGTT in a local testing
facility
l Patients were referred to the
DESMOND structured
education programme53
l Patients were offered
2-monthly appointments with
a diabetes nurse or physician
in a community peripatetic
clinic for 1 year and 4-monthly
appointments thereafter
l Clinic staff were prompted to
contact patients defaulting
from appointments
l Small financial incentives
for GPs
l Participants were tagged for
mortality with the Office for
National Statistics
l Sensitive electronic searches
of general practice records
were undertaken between
March 2009 and February
2010. If a possible event
was highlighted copies were
made of medical records.
Additional information was
obtained from hospital
medical records and
coroners’ offices as required
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Inclusion and exclusion criteria
All patients newly diagnosed with type 2 diabetes were eligible to participate in the treatment study unless
their family physician indicated that they had contraindications to the proposed study medication, an
illness with a life expectancy of < 12 months or psychological or psychiatric problems that were likely to
invalidate informed consent. Overall, 3057 eligible participants with screen-detected diabetes agreed
to take part (Denmark, n= 1533; Cambridge, n= 867; the Netherlands, n= 498; Leicester, n= 159).
Intervention
The characteristics of the interventions to promote IT in each centre have been described previously47–49,57
and are summarised in Table 1. We aimed to educate and support general practitioners (GPs) and practice
nurses in target-driven management (using medication and promotion of a healthy lifestyle) of hyperglycaemia,
blood pressure and cholesterol, based on the stepwise regimen used in the Steno-2 study.29 Treatment targets
and algorithms (Table 2) based on trial data in people with type 2 diabetes24,26,29,58,59 were the same for the
IT groups in all centres. GPs were advised to consider prescribing an angiotensin-converting enzyme (ACE)
inhibitor for patients with blood pressure ≥ 120/80mmHg or a previous cardiovascular event58 and 75mg
of aspirin daily to patients without specific contraindications. Although treatment targets were specified
and classes of medication recommended, prescribing decisions, including choice of individual drugs, were
made by practitioners and patients. Following publication of the results of the HPS,28 the treatment algorithm
included a recommendation to prescribe a statin to all patients with a cholesterol level of ≥ 3.5mmol/l.
TABLE 1 Characteristics of the ADDITION-Europe screening programmes, intervention delivery and outcome
ascertainment by study centre (continued )
Centre Screening programme Intervention delivery Outcome ascertainment
The
Netherlands
(a) Patients aged 50–69 years
were sent a letter from
their GP including the
Hoorn study Symptom Risk
Questionnaire54 and
advising those with a score
of ≥ 4 to enter a stepwise
screening programme
including capillary RBG and
FBG testing in a local
testing facility
(b) Patients aged 50–69 years
were sent a letter from
their GP including the
Hoorn study Symptom Risk
Questionnaire54 and
advising those with a score
of ≥ 6 to enter a stepwise
screening programme
including capillary FBG
testing in a local
testing facility
l Small group or practice-based
educational meetings with
GPs and nurses to discuss
treatment targets, algorithms
and lifestyle advice
l Audit and feedback included
in follow-up meetings up to
twice a year or co-ordinated
by post
l Patients were seen by
diabetes nurses who were
authorised to prescribe
medication and adjust doses
under GP supervision
l Patients were sent reminders
if annual measures
were overdue
l Small financial incentives
for GPs
l General practice records
were hand-searched and
end point and vital status
information was extracted
onto standardised forms. For
patients who had moved
practice, end-point data
were obtained by telephone
interview with their
current GP
DESMOND, Diabetes Education and Self-Management for Ongoing and Newly Diagnosed; FBG, fasting blood glucose;
GP, general practitioner; HbA1c, glycated haemoglobin; ICD-10, International Statistical Classification of Diseases and
Related Health Problems, Tenth Edition; OGTT, oral glucose tolerance test; RBG, random blood glucose.
Source: reproduced open access from Griffin et al.55
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Intensive treatment was promoted through the addition of several features to existing diabetes care. Small
group or practice-based educational meetings were arranged with GPs and nurses to discuss the treatment
targets and algorithms and lifestyle advice, including supporting evidence. Audit and feedback were
included in follow-up meetings up to twice per year (the total number of practice meetings ranged from
2 to 10) or co-ordinated by post. In the Netherlands patients were seen in general practice by diabetes
nurses who were authorised to prescribe medication and adjust doses under GP supervision. In Denmark
and Cambridge practice staff were provided with educational materials for patients. In Denmark and the
Netherlands patients were sent reminders if annual measures were overdue. In all centres practices
received additional funding to support the delivery of care (up to the equivalent of three 10-minute
consultations with a GP and three 15-minute consultations with a nurse per patient per year for 3 years).
Leicester patients were referred to the Diabetes Education and Self-Management for Ongoing and Newly
Diagnosed (DESMOND) structured education programme53 and were offered 2-monthly appointments with
a diabetes nurse or physician in a community peripatetic clinic for 1 year and 4-monthly appointments
thereafter. Clinic staff were prompted to contact patients defaulting from appointments.
In the RC group, GPs were provided only with the diagnostic test results. Patients with screen-detected
diabetes received the standard pattern of diabetes care according to the recommendations applicable in
each centre.60–63
Data collection
Centrally trained staff undertook health assessments at baseline and after 5 years, including biochemical
and anthropometric measures, and administered questionnaires, following standard operating procedures.
Staff were unaware of study group allocation. Follow-up examinations took place from September 2008
until the end of December 2009. The mean [standard deviation (SD)] follow-up period was 5.3 (1.6) years.
All biochemical measures were analysed in five regional laboratories at baseline and follow-up. Standardised
self-report questionnaires were used to collect information on education, employment, ethnicity, lifestyle
habits (smoking status, alcohol consumption), prescribed medication and health status. Questionnaires were
completed at the same health assessment visit as the anthropometric and biochemical measurements.
If participants did not complete follow-up questionnaires or measurements then the most recent values
were obtained from general practice records along with information on prescribed medication.
Primary end point
The primary end point was a composite of first cardiovascular event, including cardiovascular mortality,
cardiovascular morbidity (non-fatal MI and non-fatal stroke), revascularisation and non-traumatic
amputation. All-cause mortality and each of the individual components of the primary end point were
secondary outcomes. In each centre participants’ medical records or national registers were searched for
potential end points by staff unaware of group allocation. For each possible end point, packs containing
relevant clinical information (such as a death certificate, post-mortem report, medical records, hospital
discharge summary, electrocardiographs and laboratory results) were prepared and sent to two members
of the expert committees, who were unaware of group allocation, for independent adjudication according
to an agreed protocol using standardised case report forms. Committee members met to reach consensus
over discrepancies. The date of completion of follow-up for the primary end point was deemed to be the
date of the first primary end point, the date of remeasurement at 5 years if no end point occurred or the
date that the end-point search was undertaken if the participant did not experience an event or attend
follow-up.
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Secondary end points
Microvascular outcomes
Prespecified secondary outcomes included measures of kidney function, retinopathy and
peripheral neuropathy.
Nephropathy was assessed by the urinary albumin–creatinine ratio (ACR) and the estimated glomerular
filtration rate (eGFR). The urinary ACR was measured on spot urine and analysed at Aarhus Hospital
(Aarhus, Denmark) and Steno Diabetes Centre (Gentofte, Denmark) using a Hitachi 912 Chemistry
Analyzer (Tokyo, Japan); at Addenbrooke’s Hospital (Cambridge, UK) and Leicester Royal Infirmary
(Leicester, UK) using an Olympus AU400 Chemistry Analyzer (Tokyo, Japan); and at the SHL Centre for
Diagnostic Support in Primary Care (Etten-Leur, the Netherlands) using a Roche Hitachi Modular P
Chemistry Analyzer (Basel, Switzerland). Repeated analyses of standardised trial control samples for urine
creatinine during follow-up confirmed the reliability and precision of the laboratory methods with
coefficients of variation (CVs) < 3.4% in all laboratories. Analyses of trial and external quality control
samples of urine albumin revealed CVs between 2.0% and 9.8% in the Etten-Leur, Leicester and Gentofte
laboratories and CVs of 4.9% for low concentrations and 3.4% for high concentrations in the
Addenbrooke’s laboratory in Cambridge during the period of trial testing. Microalbuminuria was defined
as an ACR of ≥ 2.5mg/mmol for men and ≥ 3.5mg/mmol for women and macroalbuminuria was defined
as an ACR of ≥ 25mg/mmol. Nephropathy was defined as the presence of either microalbuminuria or
macroalbuminuria. The eGFR was calculated using data on serum creatinine, age, sex and ethnicity for
each individual using the Modification of Diet in Renal Disease formula64 at baseline and follow-up.
Change between the two time points was analysed as a continuous variable. Plasma creatinine was
analysed with kinetic colourimetric methods at all laboratories at baseline and follow-up except in the
Netherlands where an enzymatic method was used at follow-up. Repeated analyses of standardised
control samples for creatinine during follow-up the confirmed reliability and precision of the laboratory
methods, with CVs between 1.3% and 6.4%.
Retinopathy was assessed using gradable digital images taken using a retinal camera (two from each eye,
one with the fovea in the centre and one with the macula in the centre). In the Netherlands and Leicester
all retinal images were taken as part of the follow-up examination. In Denmark 81% of the images were
taken as part of the study follow-up, with the remainder being obtained from routine health service
records. All retinal images in Cambridge were retrieved from routine medical records. Only images taken in
the 2 years preceding the follow-up visit were included in this analysis. Information on retinal photography
devices used at the four centres is available on the study website [see www.addition.au.dk/ (accessed
30 June 2014)]. Retinal images were graded by three certified graders, who were unaware of the
participants’ study group allocation, using a quantitative grading system and subsequently categorised
according to the Early Treatment Diabetic Retinopathy Study (ETDRS) semiquantitative scale.65 Two binary
end points were then defined: (1) any retinopathy compared with no retinopathy and (2) severe or
proliferative retinopathy compared with no, mild or moderate retinopathy.
Peripheral neuropathy was assessed using the self-administered Michigan Neuropathy Screening
Instrument,66 which includes 13 questions about neuropathic symptoms. Responses to the questions are
summed to calculate the total score. Responses of ‘yes’ to items 1–3, 5, 6, 8, 9, 11, 12, 14 and 15 each
score 1 point and ‘no’ responses on items 7 and 13 each score 1 point. Item 10 is not included in the
calculation of a score for neuropathy. Participants were defined as having peripheral neuropathy if they
had a score of ≥ 7. The peripheral neuropathy scores were considered missing if categorisation was not
possible because of unanswered items.67
Patient-reported outcomes
As the participants were screen detected, no diabetes-specific measures were obtained at baseline.
At follow-up, questionnaires were used to cover both generic and diabetes-specific measures.
TRIAL DESIGN AND METHODS
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Health status was assessed using the European Quality of Life-5 Dimensions (EQ-5D), a generic
health-related quality of life questionnaire consisting of a classification system (EQ-5D profile) and a visual
analogue scale [European Quality of Life visual analogue scale (EQ-VAS)]. The EQ-5D profile was completed
by participants at baseline and follow-up; the EQ-VAS was completed at follow-up only. The EQ-5D profile
covers five domains of health (mobility, self-care, usual activities, pain/discomfort and anxiety/depression),
each with three levels of functioning: level 1, no problems; level 2, some problems; level 3, severe problems.
This results in 243 health states, which are converted to a single index (‘utility’) using a population-specific
algorithm. The standard UK value set gives utilities ranging from –0.594 to +1.00 (full health).68 A value of 0
represents death; negative values imply a health state worse than death. The EQ-VAS is a graded, vertical
line, anchored at 0 (worst imaginable health state) and 100 (best imaginable health state). Patients were
asked to mark a point on the EQ-VAS that best reflected their actual health state.69
The Short Form questionnaire-36 items (SF-36)70 generates a profile of scores on eight dimensions of
health: (1) physical functioning; (2) role limitations because of physical problems; (3) social functioning;
(4) bodily pain; (5) general mental health; (6) role limitations because of emotional problems; (7) vitality;
and (8) general health perceptions. Two summary scales can be calculated: the physical component
summary score and the mental component summary score. For all dimensions an average score can be
calculated, with a range from 0 (least favourable health state) to 100 (most favourable health state).
The SF-36 was completed at follow-up.
General well-being was assessed using the previously validated 12-item short form of the Well-Being
Questionnaire (W-BQ12),71 which measures different aspects of the well-being of individuals, including
diabetes patients. It can be scored as three subscales: negative well-being (a higher score means more
negative well-being), energy (a higher score means more energy) and positive well-being (a higher score
means more positive well-being). Each subscale consists of four items with a score range of 0–12.
Furthermore, a score for general well-being can be calculated;72 this has a score range of 0–36 and a
higher score indicates better well-being. The W-BQ12 was completed at follow-up.
Diabetes-specific quality of life was assessed using the previously validated Audit of Diabetes-Dependent
Quality of Life (ADDQoL),73 a measure of patients’ perceived importance of diabetes and its treatment and
its impact on quality of life. We used the ADDQoL 19, which includes 19 diabetes-specific items. For each
item patients are asked how things would be without diabetes, with scores ranging from –3 (a great deal
better) to 1 (worse), and to rate each item, with scores ranging from 3 (very important) to 0 (not at all
important). A weighted rating per item can be calculated by multiplying the unweighted rating by the
importance rating. The total ADDQoL score is the mean of all weighted ratings of applicable domains and
ranges from –9 (maximum negative impact of diabetes) to 3 (maximum positive impact of diabetes).
The ADDQoL was completed at follow-up.
Satisfaction with diabetes treatment was assessed using the previously validated Diabetes Treatment
Satisfaction Questionnaire (DTSQ).74 It consists of a six-item scale assessing treatment satisfaction and two
items assessing the perceived frequency of hyperglycaemia and hypoglycaemia. The treatment satisfaction
score ranges from 0 (very dissatisfied) to 36 (very satisfied). The DTSQ was completed at follow-up.
Sample size
An individually randomised trial would have required a total of 2700 individuals (1350 per group) to detect
a 30% reduction in the cumulative risk of the primary end point at a 5% significance level and with 90%
power, allowing for 10% loss to follow-up and assuming an event rate in the RC group of 3% per year
(based on results from the UKPDS24). We expected a minimal effect of clustering within general practices,
with an estimated intracluster correlation coefficient of 0.01; assuming an average of 10 participants per
general practice, the design effect was 1.09 and so we inflated the estimated sample size for this cluster
trial to 3000.
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Statistical analysis
The analysis and reporting of this trial were undertaken in accordance with the Consolidated Standards of
Reporting Trials (CONSORT) guidelines [see www.consort-statement.org/ (accessed 27 January 2016)].
Statistical analysis was undertaken in Stata 11.1 (StataCorp LP, College Station, TX, USA), SAS v9.2
(SAS Institute Inc., Cary, NC, USA) and Review Manager v5.1 (The Cochrane Collaboration, The Nordic
Cochrane Centre, Copenhagen, Denmark), following a predefined analysis plan, which was finalised
before preparation of the end-point data set, agreed with the Trial Steering Committee and deposited on
the study website (see www.addition.au.dk/). The primary comparative analyses between the randomised
groups were conducted on an intention-to-treat (ITT) basis without imputation of missing data.
Preliminary analyses
We summarised the baseline characteristics of individuals and general practices within each randomised
group, by centre and overall.
Changes in mean values or percentages of other clinical and medication variables from baseline to follow-up
were summarised in each randomised group and intervention effects and 95% CIs for these changes
were estimated using the methods described in the primary and secondary analysis sections. We also
calculated 10-year modelled CVD risk using the UKPDS model (version 3)75 at 5 years post diagnosis.
This is a diabetes-specific risk assessment tool that estimates the absolute risk of fatal or non-fatal CVD
within a defined time frame. The variables include age, sex, ethnicity, smoking status, glycated haemoglobin
(HbA1c) level, systolic blood pressure, total to high-density lipoprotein (HDL) cholesterol ratio, atrial fibrillation
(AF), previous MI or stroke, macroalbuminuria (ACR ≥ 30mg/mmol), microalbuminuria (ACR ≥ 2.5mg/mmol
in men or ≥ 3.5mg/mmol in women), duration of diagnosed diabetes and body mass index. We did
not have data on AF in ADDITION-Europe participants and so all individuals were coded as zero (no AF).
Centre-specific estimates of the difference in modelled CVD risk between treatment groups were combined
using fixed-effects meta-analysis. Odds ratios (ORs) of meeting each of three treatment targets [HbA1c
< 53mmol/l (7.0%) if HbA1c > 6.5%; blood pressure ≤ 135/85mmHg if ≥ 120/80mm Hg; cholesterol
< 5mmol/l without ischaemic heart disease or < 4.5mmol/l with ischaemic heart disease) comparing IT with
RC were also estimated.
Primary analyses: cardiovascular outcomes
We plotted the cumulative probability of the primary end point. To assess intervention effects we used Cox
regression to estimate a hazard ratio and 95% CI within each centre. As there were few participants and
hence events in the Leicester centre, data for the primary end point and its components were grouped
with data from Cambridge, the other UK centre. Because randomisation was at the practice level, robust
standard errors (SEs) were calculated that take into account the two-level structure of the data (individuals
clustered within practices) and any potential correlation between individuals within practices. We
calculated the intracluster correlation coefficient for the primary end point. We combined centre-specific
log-hazard ratios and SEs using fixed-effects meta-analysis and calculated the I2-statistic, which represents
the proportion of variability (in log-hazard ratios) between centres that is due to heterogeneity. We tested
the proportional hazards assumption by including a parameter for treatment × time interaction in each
centre-specific Cox regression model. We analysed continuous intermediate end points within each centre
using normal errors regression, with adjustment for the baseline value of the end point, excluding
individuals who died or who were lost to follow-up. We combined the estimated differences in mean
change from baseline across centres using fixed-effects meta-analysis. In the regression models we
included individuals with a missing value of the outcome at baseline using the missing indicator method;76
variables with a skewed distribution were log-transformed. We estimated the effect of the intervention on
prescribing end points using logistic regression within each centre and combined the estimated ORs across
centres using fixed-effects meta-analysis. We undertook sensitivity analyses by excluding follow-up clinical
TRIAL DESIGN AND METHODS
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data obtained from general practice records and prespecified subgroup analyses for the primary end point
by including interaction terms between the intervention group and patient age and self-reported history of
CVD, which were then pooled across centres. The cumulative incidence of the composite cardiovascular
end point was calculated using the method for competing risks described by Gooley et al.,77 with the
competing events here being the primary end point and death from non-cardiovascular causes.
Secondary analyses: all-cause mortality
All-cause mortality data were analysed using the method described in the previous section for the
composite CVD end point. Kaplan–Meier estimates of cumulative incidence were calculated.
Secondary analyses: microvascular outcomes
Binary end points (any albuminuria and any retinopathy) were analysed using a logistic regression model
estimating the OR and 95% CI for the comparison between IT and RC separately within each centre.
The continuous end points (ACR, eGFR) were analysed using a normal errors regression model with
adjustment for baseline.
In both logistic and normal errors regression models, given the cluster-randomised design, SEs were
adjusted using the cluster option in Stata to allow for correlation between patients within practices.
The estimated ORs and differences in means from the four centres were pooled using fixed-effects
meta-analysis and a forest plot was used to display the results. The I2-statistic, representing the proportion
of variability between centres that is due to heterogeneity, was calculated. Intracluster correlation
coefficient values were estimated for all of the microvascular outcomes.
Prespecified analyses of potential interactions between randomised groups and subgroups defined by the
following baseline variables were undertaken: age (< 60 and ≥ 60 years), sex, HbA1c [< 6.6% (< 49mmol/mol)
and ≥ 6.6% (≥ 49mmol/mol), which was the median value] and the presence of albuminuria. For ACR and
eGFR, those participants with a missing baseline value of the variable were included in the analysis using
the missing indicator method.76 A sensitivity analysis using multiple imputation was used to investigate the
impact of missing data on the retinopathy and peripheral neuropathy end points.
Secondary analyses: patient-reported outcomes
We presented mean scores and SDs for all PROMs at follow-up by centre and by randomised group.
We used linear mixed-effects regression models to estimate the difference in each PROM at follow-up and
95% CI, comparing the IT group with the RC group. A random effect per general practice was included to
account for intracluster correlation. All PROMs were left skewed. As an alternative to transformation, we
wished to control for baseline levels of PROMs. These were not available for all measures so we included
baseline EQ-5D score as a proxy for baseline quality of life; correction for baseline EQ-5D score greatly
improved the normality of the residuals. The estimated differences in means from the four centres were
then pooled using random-effects meta-analysis and a forest plot was used to display the estimated
mean differences and 95% CIs for each centre and overall. We calculated the I2-statistic to represent the
proportion of variability between centres attributable to heterogeneity.
Individuals who were lost to follow-up or who did not complete both the baseline and the follow-up
questionnaires were excluded. Patients with missing data may be those who experienced more serious
illness and greater disability and therefore these missing data are unlikely to be ‘missing completely at
random’ but will rather be ‘missing at random’. Simply excluding these patients may lead to selection bias
and therefore we used multiple imputation78 to perform a sensitivity analysis, imputing five data sets using
patient characteristics at baseline and at 5 years’ follow-up and including all patients who were alive at
follow-up.
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Patient and public involvement
In the development of the ADDITION-Cambridge study, patients were involved in two pilot studies. The
first was to assess the feasibility and uptake of the diabetes screening programme and to examine the
effects of invitation to diabetes screening on anxiety, self-rated health and illness perceptions.79 The second
was a qualitative study of patients’ experiences of being screened for diabetes.80 Further qualitative work
was undertaken exploring practitioners’ experiences of taking part in the main ADDITION-Cambridge
study.81 In terms of patient involvement during the 5-year follow-up phase of the trial, we sent a
newsletter to all ADDITION-Cambridge participants in 2008 outlining the results to date and informing
them of our intention to invite them back for the 5-year follow-up assessment. We said to participants:
‘[a]ny ideas that you may have on the conduct and planning of the 5-year follow-up health check would be
welcomed – please get in touch if you have any comments’. Responses fed into our 5-year planning. We
also sent participants a newsletter in May 2012 with the 5-year study results and invited them and a guest
to attend a local meeting during June/July 2012 where they had the chance to meet with ADDITION staff
and hear about the results of the study. The five meetings were very well received and gave this special
group of patients a chance to ask questions about the study and their diabetes treatment. Comments
ranged from ‘very informative’ and ‘the content was useful and excellent’ to ‘the results of the study will
motivate me to work harder at controlling my diabetes’. There was very strong support for being involved
with a 10-year follow-up study. Similar feedback to study participants took place in the Netherlands
and Denmark.
In ADDITION-Leicester, the intervention model was particularly suited to patient and public involvement,
with ongoing contact with the clinical care team facilitating continuity and dialogue. IT participants were
consulted and offered continued post-trial care delivered in a setting of their choice (primary or secondary
care). A number of participants have become members of the local patient and public involvement group
and are actively involved in steering local research. A newsletter describing the final results and thanking
participants for their involvement was sent following completion of the 5-year outcome ascertainment for
the entire cohort (July 2014). A significant number of participants were identified as being at high risk of
diabetes during the ADDITION-Leicester study and have subsequently been involved with other studies
aimed at the prevention of diabetes. We have also developed a black and minority ethnic panel that has
contributed more widely to diabetes research in hard-to-reach groups.
TRIAL DESIGN AND METHODS
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Chapter 3 Trial results
O f the 343 general practices that were randomised, 318 (RC, n= 157; IT, n= 161) completed screeningand included eligible participants. Participating practices in the Netherlands and the UK have been
described previously.43,48,49 All four centres had a diabetes prevalence of 3.5% and a nationally
representative mean patient list of ≈7000 individuals (n= 7378 RC group, n= 7160 IT group). Baseline
sociodemographic, biochemical, clinical and treatment characteristics of individuals in the two randomised
groups were well matched overall (see Table 3). However, more patients were identified in IT than in RC
practices in Denmark (n= 910 and 623, respectively) and more IT than RC participants had a previous
history of ischaemic heart disease [International Statistical Classification of Diseases and Related Health
Problems, Tenth Edition (ICD-10) codes I20–25: 11.2% vs. 8.5%, respectively] or other cardiac diagnoses
(ICD-10 codes I30–I52: 8.4% vs. 4.5%, respectively). The mean age of ADDITION-Europe participants was
60 years and 58% were male, 94% were Caucasian and 41% were employed. Levels of CVD risk factors
among participants at diagnosis were high and many participants were not receiving treatment for these
risk factors.50 Participant and practice flows are shown in Figure 1 (CONSORT diagram).
Of those who were still alive in 2009, 2400 (84%) individuals returned to a clinical research facility for a
5-year follow-up health assessment. We obtained biochemical and clinical data from GP records for a
further 328 (11.5%) participants. Compared with those with follow-up data, participants with missing data
were more likely to be from an ethnic minority group (10.2% vs. 5.7%; p= 0.04) and to have higher
cholesterol (5.9 mmol/l vs. 5.6 mmol/l; p= 0.004) and low-density lipoprotein (LDL) cholesterol values
(3.7 mmol/l vs. 3.4mmol/l; p= 0.009) at baseline.
Changes in biochemical, clinical and treatment variables in the two trial groups are shown in Table 3.
Prescription of antihypertensive, glucose-lowering and lipid-lowering medication increased in both groups.
At follow-up, compared with the RC group, approximately 10% more participants were prescribed
glucose-lowering, antihypertensive and lipid-lowering medication in the IT group. In addition, 15% more IT
patients were prescribed ACE inhibitors or angiotensin receptor blockers (ARBs) and 30% more IT patients
were prescribed aspirin at follow-up. Cardiovascular risk factors in both groups improved over 5 years of
follow-up. The modest but statistically significant between-group differences in change from baseline for
total and LDL cholesterol, systolic and diastolic blood pressure and HbA1c favoured the IT group.
The 10-year modelled CVD risk was 27.3% (SD 13.9%) at baseline in the whole trial cohort and 21.3%
(SD 13.8%) at 5 years. Across all four centres there was a reduction in modelled CVD risk from baseline to
5 years in both the RC group (–5.0%, SD 12.2%) and the IT group (–6.9%, SD 9.0%). Figure 2 shows the
distribution of CVD risk at baseline and follow-up by treatment group; the distribution of modelled CVD
risk shifted to the left for both groups.
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A
llo
ca
ti
o
n
En
ro
lm
en
t
Allocated to screening and IT
 of diabetes (167 practices)
• Received allocated intervention 
   (n = 161 practices)
   • Total number of participants, n = 1678
   • Median number of participants per
      practice, n = 8
   • Range of participants per practice, 
      n = 1– 46
• Did not receive allocated intervention
   (n = 6 practices)
   • Practices withdrew from the study
      before screening commenced, n = 5
   • Practice undertook screening but 
      did not find any eligible participants 
      to include in the treatment study, n = 1
Allocated to screening and RC
 of diabetes (176 practices)
• Received allocated intervention 
   (n = 157 practices)
   • Total number of participants, n = 1379
   • Median number of participants per
      practice, n = 6
   • Range of participants per practice,  
      n = 1– 42
• Did not receive allocated intervention
   (n = 19 practices)
   • Practices withdrew from the study
      before screening commenced, n = 11 
   • Practice undertook screening but 
      did not find any eligible participants 
      to include in the treatment study, n = 8
Fo
llo
w
-u
p
Primary end point
• Practices lost to follow-up, n = 0
• Participants lost to follow-up, n = 0
• Participants with primary
   end-point data, n = 1678
Participant status at 5-year follow-up
• Died, n = 104 (6%)
• Attended 5-year visit at clinical 
   research facility, n = 1352 (86%)
• With biochemistry data, n = 1532 (97%)
Primary end point
• Practices lost to follow-up, n = 0
• Participants withdrew consent to 
   take part in the study; it was not 
   therefore possible to ascertain primary 
   end-point status for these individuals
   1377 participants with primary 
   end-point data, n = 2 (0.1%) 
Participant status at 5-year follow-up
• Died, n = 92 (7%)
• Attended 5-year visit at clinical 
   research facility, n = 1048 (81%)
• With biochemistry data, n = 1241 (96%)
A
n
al
ys
is
Analysed
• Practices, n = 161
• Participants, n = 1678
• Median number of participants per
   practice, n = 8
• Range of participants per practice,  
   n = 1– 46
Excluded from analysis
• Participants, n = 0
Participants
• Participants analysed, 
   n = 1678/1678 (100%)
Analysed
• Practices, n = 157
• Participants, n = 1377
• Median number of participants per
   practice, n = 6
• Range of participants per practice,  
   n = 1– 42
Participants
• Participants analysed, 
   n = 1377/1379 (99.9%)
Excluded from analysis
• Participants who withdrew consent 
   to take part in the study, n = 2
1312 practices invited to join the study
379 practices agreed to participate
343 practices randomised
Excluded (36 practices):
• Limited health service resources
   (19 practices in Denmark)
• Allocated to pilot study
   (three practices in Cambridge)
• Randomised to a no-screening
   control arm (five practices in
   Cambridge)
• No search possible 
   (nine practices in Leicester)
FIGURE 1 Practice and participant flows in the ADDITION-Europe trial. Source: reproduced open access from
Griffin et al.55
DOI: 10.3310/hta20640 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 64
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Simmons et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
19
Risk at baseline
Risk at follow-up
0.04
0.03
0.02
D
en
si
ty
0.01
0
0 50
10-year risk score (%)
100
(a)
0.04
(b)
0.03
0.02
D
en
si
ty
0.01
0
0 50
10-year risk score (%)
100
Risk at baseline
Risk at follow-up
FIGURE 2 Distribution of the UKPDS (version 3) modelled CVD risk score at baseline and 5 years’ follow-up in the
ADDITION-Europe trial cohort by treatment group. (a) RC; and (b) IT. Source: reproduced open access from
Black et al.82
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
20
Within all four centres the modelled CVD risk was lower in the IT group than in the RC group at 5 years
(Figure 3). The difference between the groups varied from –0.9% (95% CI –3.6% to 1.7%) in Cambridge
to –4.8% (95% CI –8.4% to –1.3%) in the Netherlands. There was moderate variation between centres
(I2= 53.6%). For all centres combined, the 10-year modelled CVD risk was significantly lower (–2.0%,
95% CI –3.1% to –0.9%) in the IT group after adjustment for baseline cardiovascular risk and clustering
by general practice.
Figure 4 shows the percentage of participants meeting treatment targets for cholesterol, HbA1c and blood
pressure in each group at baseline and follow-up. More patients met treatment targets at follow-up than
at baseline in both groups. The proportion meeting the targets was higher in the IT group than in the RC
group. There was no difference between groups in the percentage of those reporting hypoglycaemia
(χ2= 4.44; p= 0.62).74 The results were the same when excluding participants with follow-up clinical data
obtained from GP records.
Centre n (% of randomised) Mean difference (95% CI) Weight
Cambridge
Leicester
Denmark
The Netherlands
Overall (I2 = 53.6%, p = 0.091)
619 (76%)
133 (86%)
1017 (72%)
332 (69%)
–8 0 4
–0.94 (–3.60 to 1.72)
–4.82 (–8.35 to –1.30)
–1.17 (–2.67 to 0.34)
–3.87 (–6.34 to –1.41)
–2.02 (–3.12 to –0.92)
17.1%
9.7%
53.3%
19.9%
Favours intensive treatment Favours routine care
Difference in 10-year modelled CVD risk score
FIGURE 3 Difference in the UKPDS (version 3) modelled CVD risk score between treatment groups at 5 years’
follow-up in the ADDITION-Europe trial cohort, adjusted for baseline risk and accounting for clustering by general
practice. Source: reproduced open access from Black et al.82
DOI: 10.3310/hta20640 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 64
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Simmons et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
21
02040
Patients achieving target (%)
6080
B
as
el
in
e
fo
llo
w
-u
p
B
as
el
in
e
fo
llo
w
-u
p
B
P 
<
 1
35
/8
5 
m
m
H
g
B
as
el
in
e
fo
llo
w
-u
p
B
as
el
in
e
fo
llo
w
-u
p
C
h
o
le
st
er
o
l <
 5
 m
m
o
l/l
 (
n
o
 C
V
D
)/
<
 4
.5
 m
m
o
l/l
 (
C
V
D
)
B
as
el
in
e
fo
llo
w
-u
p
B
as
el
in
e
fo
llo
w
-u
p
H
b
A
1c
 <
 7
%
R
C
IT
FI
G
U
R
E
4
Pe
rc
en
ta
g
e
o
f
p
ar
ti
ci
p
an
ts
in
ea
ch
g
ro
u
p
o
f
th
e
A
D
D
IT
IO
N
-E
u
ro
p
e
tr
ia
l
(±
1
SE
)
fo
r
w
h
o
m
th
e
tr
ea
tm
en
t
ta
rg
et
s
w
er
e
m
et
at
b
as
el
in
e
an
d
fo
llo
w
-u
p
at
a
m
ea
n
o
f
5.
3
ye
ar
s.
B
P,
b
lo
o
d
p
re
ss
u
re
.S
o
u
rc
e:
re
p
ro
d
u
ce
d
o
p
en
ac
ce
ss
fr
o
m
G
ri
ff
in
et
al
.5
5
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
22
Primary analyses: cardiovascular outcomes
Primary end-point data were available for 99.9% (3055/3057) of participants. In total, 238 first
cardiovascular events occurred during a mean (SD) follow-up period of 5.3 (1.6) years (Table 4). There
were 121 events among 1678 participants (7.2%) in the IT group (incidence 13.5, 95% CI 11.3 to 16.1
per 1000 person-years) and 117 events among 1377 participants (8.5%) in the RC group (incidence 15.9,
95% CI 13.3 to 19.1 per 1000 person-years). The hazard ratio for the IT group compared with the RC
group was 0.83 (95% CI 0.65 to 1.05; p= 0.12). The cumulative probability for the primary CVD end
point appeared to diverge after 4 years of follow-up (Figure 5). In predefined subgroup analyses there
were no interactions between the intervention and age or previous cardiovascular event (p> 0.1).
The p-value was calculated using Cox regression and fixed-effects meta-analysis.
However, estimated hazard ratios were 0.70 (95% CI 0.52 to 0.95) in those aged ≥ 60 years and 1.12
(95% CI 0.70 to 1.79) in those aged < 60 years. Hazard ratios for individual components of the composite
end point all favoured the IT group (see Table 4), although none achieved statistical significance (Figure 6).
There were no amputations as first events. The intracluster correlation coefficient for the primary end point
was 0.002 (Denmark 0.014, UK 0.0000016, the Netherlands 0.025). This suggests that the cluster design
had little effect on study power.
In total, there were 196 deaths (n= 60 cardiovascular, n= 97 cancer and n= 39 other), 104 (6.2%) in
the IT group (mortality rate 11.6, 95% CI 9.6 to 14.0 per 1000 person-years) and 92 (6.7%) in the RC
group (mortality rate 12.5, 95% CI 10.2 to 15.3 per 1000 person-years) (see Table 4). The combined
mortality hazard ratio for the IT group compared with the RC group was 0.91 (95% CI 0.69 to 1.21). A
Kaplan–Meier plot is shown in Figure 7 and country-specific hazard ratios in Figure 8. The heterogeneity of
results between countries was not statistically significant. In the UK there were significantly fewer deaths in
the IT group, whereas in Denmark there was a non-significant reduction in cumulative risk in the RC group.
TABLE 4 Cardiovascular events and all-cause mortality in the ADDITION-Europe trial
End point
RC (n= 1377),
n (%)
IT (n= 1678),
n (%)
IT vs. RC
Hazard ratioa 95% CI I2 (%)b p-valuec
Primary end point: composite
cardiovascular eventsd
117 (8.5) 121 (7.2) 0.83 0.65 to 1.05 0 0.12
Components of primary end point
CVD death 22 (1.6) 26 (1.5) 0.88 0.51 to 1.51 52
MI 32 (2.3) 29 (1.7) 0.70 0.41 to 1.21 0
Stroke 19 (1.4) 22 (1.3) 0.98 0.57 to 1.71 0
Revascularisation 44 (3.2) 44 (2.6) 0.79 0.53 to 1.18 0
Amputation 0 0 – – –
Total mortality 92 (6.7) 104 (6.2) 0.91 0.69 to 1.21 55
a Hazard ratios are first estimated within each country using Cox regression with Huber–White adjustment of SEs for
clustering within practice and are then combined across countries using fixed-effects meta-analysis.
b I2 is an estimate of the heterogeneity between countries.
c A p-value was calculated for the primary end point only.
d Any of the following: CVD death, MI, stroke, revascularisation or amputation.
Note
Individual country-specific estimates are displayed in forest plots (see Figure 6).
Source: reproduced open access from Griffin et al.55
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FIGURE 5 Cumulative incidence of the composite cardiovascular end point in the RC and IT groups of the
ADDITION-Europe trial (p= 0.12). Source: reproduced open access from Griffin et al.55
Country Hazard ratio (95% CI)
CVD death
Denmark
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FIGURE 6 The relative risk of the development of cardiovascular death, non-fatal MI, non-fatal stroke and
revascularisation as a first event and the composite cardiovascular end point by country and overall in the IT group
compared with the RC group. Source: reproduced open access from Griffin et al.55
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
Secondary analyses: microvascular outcomes
Of the 2861 patients still alive at 5 years, 2493 (87.1%), 2710 (94.7%) and 2312 (80.8%) had data for
urinary ACR, eGFR and peripheral neuropathy, respectively. Retinal photographs were retrieved for 2190
(76.5%) participants.
At 5 years’ follow-up any albuminuria was present in 316 (22.7%) participants in the IT group and 269
(24.4%) participants in the RC group. Macroalbuminuria was present in 56 (4.0%) and 37 (3.4%)
participants in the IT and RC groups, respectively. Centre-specific ORs for any albuminuria favoured the IT
group, but the pooled OR was not statistically significant (0.88, 95% CI 0.72 to 1.07; Figure 9). The
pooled OR for macroalbuminuria was 1.15 (95% CI 0.76 to 1.74). In both groups the urinary ACR
increased between baseline and follow-up. In the IT group the mean (SD) increase was 1.45 (SD 0.60)
mg/mmol and in the RC group the mean (SD) increase was 1.30 (0.66) mg/mmol. The overall difference in
means was –0.02 (95% CI –0.96 to 0.91) mg/mmol. There were no significant interactions between study
group and any of the subgroups.
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FIGURE 7 Kaplan–Meier estimates of all-cause mortality in the RC and IT groups in the ADDITION-Europe trial.
Source: reproduced open access from Griffin et al.55
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FIGURE 8 The relative risk of all-cause mortality by country and overall in the IT group compared with the RC
group in the ADDITION-Europe trial. Source: reproduced open access from Griffin et al.55
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The mean (SD) eGFR increased between baseline and follow-up in both the IT group and the RC group
[IT 4.31 (0.49) ml/minute, RC 6.44 (0.90) ml/minute; difference in means –1.39 (95% CI –2.97 to 0.19)
ml/minute]. There were no significant interactions between treatment group and any of the subgroups
concerning eGFR. The number of missing data was equally distributed between the two groups.
Retinopathy was present in 125 (10.1%) participants in the IT group and 116 (12.1%) patients in the RC
group. Centre-specific ORs favoured the IT group but the pooled OR was not statistically significant
(0.84, 95% CI 0.64 to 1.10) (see Figure 9). Imputation of missing values did not affect the estimates.
Individuals without retinal images at follow-up had significantly higher baseline mean HbA1c levels than
individuals with retinal data [7.18% (55mmol/mol) vs. 6.99% (53mmol/mol), respectively; p= 0.044].
However, there was no difference between randomised groups (interaction p-value= 0.78). There was a
significant interaction between retinopathy, randomised group and baseline HbA1c level (p= 0.007).
IT appeared to be more effective among individuals with HbA1c ≥ 6.6% (≥ 49mmol/mol) at baseline
(OR 0.65, 95% CI 0.45 to 0.93) than among individuals with HbA1c < 6.6% (< 49mmol/mol) at baseline
(OR 1.17, 95% CI 0.75 to 1.82). There was no evidence of an interaction with either age or sex. Severe
retinopathy was present in one participant in the IT group and in seven participants in the RC group.
Peripheral neuropathy was present in 63 (4.9%) participants in the IT group and 60 (5.9%) participants in
the RC group (pooled OR 0.95, 95% CI 0.68 to 1.34) (see Figure 9). Non-responders to the neuropathy
questionnaire had a higher body mass index (p= 0.055) and were more likely to be from a ethnic minority
group (p= 0.004) than responders. Imputation of missing values did not affect the estimates.
The overall intracluster correlation coefficient values were as follows: retinopathy 0.014 (95% CI 0.00017
to 0.55), albuminuria 0.025 (95% CI 0.0066 to 0.091) and neuropathy 0.011 (95% CI 4.6 × 10–7 to 1).
These results indicate that the impact of clustering on study power was small.
Secondary analyses: patient-reported outcomes
Data from 2861 participants were included in the multiple imputation analyses. Patients who completed
questionnaires at baseline and follow-up (n= 2217) were more likely than those who did not complete
questionnaires (n= 644) to be male (59.5% vs. 50.8%), of white ethnicity (95.2% vs. 89.9%) and
employed (44.8% vs. 32.7%). Questionnaire completers were also less likely to smoke (24.3% vs. 34.0%),
had higher levels of alcohol consumption (median 5 units per week vs. 3 units per week) and had higher
EQ-5D scores (median 0.85 vs. 0.81) at baseline. They also had lower systolic blood pressure levels
(148.5mmHg vs. 151.4mmHg). Other characteristics were comparable between treatment groups (data
not shown).
Table 5 shows the PROM scores at follow-up, separately for each centre and by randomised group. EQ-5D
values did not change between diagnosis and follow-up: the median (interquartile range) score was 0.85
(0.73 to 1.00) at baseline and 0.85 (0.73 to 1.00) at 5 years’ follow-up.
The mean differences in PROMs comparing the IT group with the RC group are shown in Figures 10–13.
There were no statistically significant differences in health status (see Figure 10), well-being (see Figure 11),
diabetes-specific quality of life (see Figure 12) and satisfaction with diabetes treatment (see Figure 13)
between the two groups. There was some heterogeneity between centres. The I2-statistic varied between
41% (W-BQ-positive) and 73% (EQ-VAS).
Multiple imputation analyses resulted in slightly different point estimates. However, the overall patterns
remained the same and there were no statistically significant differences in any of the PROMs (results
not shown).
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–0.2
Centre Weight (%) Mean difference (95% CI)
EQ-5D
Cambridge
Denmark
Leicester
The Netherlands
Total
Heterogeneity: I2 = 49%
30.6
38.9
8.5
22.0
0.02 (–0.01 to 0.05)
–0.02 (–0.04 to 0.00)
–0.02 (–0.09 to 0.06)
–0.03 (–0.07 to 0.01)
–0.01 (–0.03 to 0.02)
EQ-VAS
Cambridge
Denmark
Leicester
The Netherlands
Total (95% CI)
Heterogeneity: I2 = 73%
28.1
32.0
13.0
26.9
2.72 (–0.09 to 5.52)
–1.05 (–3.00 to 0.90)
–8.37 (–15.15 to –1.59)
–1.87 (–4.92 to 1.18)
–1.17 (–4.20 to 1.87)
SF-36 PCS
Cambridge
Denmark
Leicester
The Netherlands
Total (95% CI)
Heterogeneity: I2 = 44%
26.4
40.4
10.5
22.7
0.83 (–0.96 to 2.61)
–0.32 (–1.36 to 0.72)
–3.78 (–7.30 to –0.26)
0.42 (–1.63 to 2.46)
–0.21 (–1.48 to 1.05)
SF-36 MCS
Cambridge
Denmark
Leicester
The Netherlands
Total (95% CI)
Heterogeneity: I2 = 50%
33.1
38.0
7.3
21.6
1.14 (–0.14 to 2.41)
–0.63 (–1.70 to 0.44)
–1.51 (–5.33 to 2.31)
–0.64 (–2.53 to 1.26)
–0.01 (–1.21 to 0.99)
–0.1
Favours IT
0.1 0.2
Favours RC
–20 –10
Favours IT
10 20
Favours RC
–20 –10
Favours IT
10 20
Favours RC
–20 –10
Favours IT
10 20
Favours RC
FIGURE 10 Mean difference in health status between the IT group and the RC group by centre (boxes) after
5 years’ follow-up in the ADDITION-Europe trial and pooled estimates (diamonds) calculated by random-effects
meta-analysis. Horizontal bars and diamond widths denote 95% CIs and box sizes indicate relative weight in
the analysis. MCS, mental component summary; PCS, physical component summary. Source: reproduced from
van den Donk et al.,84 under the Creative Commons Attribution Noncommercial licence.
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Centre Weight (%) Mean difference (95% CI)
W-BQ-general
Cambridge
Denmark
Leicester
The Netherlands
Total
Heterogeneity: I2 = 66%
30.7
34.7
11.7
22.9
0.81 (–0.10 to 1.71)
–0.60 (–1.28 to 0.08)
–2.21 (–4.64 to 0.22)
–0.45 (–1.82 to 1.18)
–0.32 (–1.31 to 0.66)
W-BQ-negative
Cambridge
Denmark
Leicester
The Netherlands
Total (95% CI)
Heterogeneity: I2 = 45%
30.3
41.6
5.1
23.0
–0.28 (–0.61 to 0.06)
0.10 (–0.12 to 0.32)
0.78 (–0.33 to 1.89)
0.06 (–0.37 to 0.48)
0.01 (–0.25 to 0.27)
W-BQ-positive
Cambridge
Denmark
Leicester
The Netherlands
Total (95% CI)
Heterogeneity: I2 = 41%
32.0
40.7
8.7
18.6
0.35 (–0.28 to 0.57)
–0.31 (–0.63 to 0.01)
–0.99 (–2.06 to 0.09)
–0.13 (–0.80 to 0.54)
–0.19 (–0.53 to 0.15)
W-BQ-energy
Cambridge
Denmark
Leicester
The Netherlands
Total (95% CI)
Heterogeneity: I2 = 54%
31.3
35.0
11.3
22.4
0.35 (–0.01 to 0.72)
–0.21 (–0.52 to 0.10)
–0.48 (–1.37 to 0.41)
–0.08 (–0.61 to 0.45)
–0.04 (–0.38 to 0.31)
–6 –3
Favours IT
3 6
Favours RC
–2 –1
Favours RC
1 2
Favours IT
–2 –1
Favours IT
1 2
Favours RC
–2 –1
Favours IT
1 2
Favours RC
FIGURE 11 Mean difference in W-BQ12 scores between the IT group and the RC group by centre (boxes) after
5 years’ follow-up in the ADDITION-Europe trial and pooled estimates (diamonds) calculated by random-effects
meta-analysis. Horizontal bars and diamond widths denote 95% CIs and box sizes indicate relative weight in
the analysis. Source: reproduced from van den Donk et al.,84 under the Creative Commons Attribution
Noncommercial licence.
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Centre Weight (%) Mean difference (95% CI)
ADDQol
Cambridge
Denmark
Leicester
The Netherlands
Total
Heterogeneity: I2 = 50%
29.4
38.0
2.5
30.1
–0.07 (–0.28 to 0.13)
0.02 (–0.13 to 0.17)
–1.23 (–2.25 to –0.21)
0.02 (–0.18 to 0.22)
–0.04 (–0.20 to 0.13)
–2 –1
Favours IT
1 2
Favours RC
FIGURE 12 Mean difference in ADDQoL scores between the IT group and the RC group by centre (boxes) after
5 years’ follow-up in the ADDITION-Europe trial and pooled estimates (diamonds) calculated by random-effects
meta-analysis. Horizontal bars and diamond widths denote 95% CIs and box sizes indicate relative weight in
the analysis. Source: reproduced from van den Donk et al.,84 under the Creative Commons Attribution
Noncommercial licence.
Centre Weight (%) Mean difference(95% CI)
DTSQ
Cambridge
Denmark
Leicester
The Netherlands
Total
Heterogeneity: I2 = 56%
34.1
32.9
7.3
25.8
–0.29 (–1.15 to 0.56)
–0.99 (–1.90 to –0.08)
–4.39 (–7.52 to –1.25)
–0.40 (–1.63 to 0.84)
–0.85 (–1.76 to 0.07)
–6 –3
Favours IT
3 6
Favours RC
FIGURE 13 Mean difference in DTSQ scores between the IT group and the RC group by centre (boxes) after 5 years’
follow-up in the ADDITION-Europe trial and pooled estimates (diamonds) calculated by random-effects
meta-analysis. Horizontal bars and diamond widths denote 95% CIs and box sizes indicate relative weight in
the analysis. Source: reproduced from van den Donk et al.,84 under the Creative Commons Attribution
Noncommercial licence.
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Chapter 4 Economic evaluation
This chapter reports two analyses related to the cost-effectiveness of early IT of type 2 diabetes. First, weassessed the performance of the UKPDS outcomes model [UKPDS-OM, version 1.3; © Isis Innovation Ltd
2010; see www.dtu.ox.ac.uk/outcomesmodel (accessed 27 January 2016)]85 in predicting CVD risk in the
ADDITION-Europe population; we wanted to investigate its suitability for modelling longer-term outcomes
and costs for the ADDITION-Europe cohort. The second analysis concerns the short-term (1–6 years
within-trial analysis) and long-term (10–30 years based on decision modelling) cost-effectiveness of the
ADDITION intervention in the UK from a UK payer (NHS) perspective.
Validating the UK Prospective Diabetes Study outcomes model
Accurate prediction of cardiovascular risk among individuals with diabetes is important for providing
prognostic information and targeting treatment to those at highest risk. It is also a key component of
economic evaluations of interventions aimed at reducing the disease burden of diabetes and improving the
quality and length of life for those with this chronic condition.
The UKPDS-OM is a cost-effectiveness analysis tool. It was derived from the UKPDS, a multicentre
randomised controlled trial among 5102 individuals with newly diagnosed type 2 diabetes.85 Participants
were recruited from 23 UK centres.86 The UKPDS-OM has been validated for the prediction of CVD and
other complications in internal and external cohorts of people with clinically diagnosed diabetes. The
observed and predicted cumulative incidence of CVD complications from diagnosis to 12 years’ follow-up
were very similar when using an internal cohort.85 Results varied from poor to moderate in terms of
discrimination, calibration and absolute risk for external cohorts,87,88 with the UKPDS-OM tending to
overestimate CVD risk.89
The UKPDS-OM was developed using data from individuals recruited between 1977 and 1997. The
treatment and costs of diabetes and related complications have changed since this time. The variables
assessed by the model are also likely to vary over time and between countries. As such, we aimed to
evaluate the performance of the UKPDS-OM in the ADDITION-Europe study, which included a
multinational contemporary cohort of individuals with screen-detected diabetes.
Methods
The 5-year accumulated absolute risks of MI and stroke were estimated for each participant in the
ADDITION-Europe study using the UKPDS-OM.85 The model includes information on age at diagnosis, sex,
ethnicity, duration of diabetes, weight, height, smoking status, presence or absence of AF, PVD, systolic
blood pressure, HbA1c, total cholesterol, HDL cholesterol and years since pre-existing CVD events. Values
for smoking status, systolic blood pressure, HbA1c, total cholesterol and HDL cholesterol were included at
both baseline and 5 years’ follow-up.
As information on AF and PVD were not collected at baseline in the ADDITION-Europe study, and given
that all patients had newly diagnosed diabetes, these variables were set to 0. The number of years since
pre-existing ischaemic heart disease, congestive heart failure, amputation, blindness and renal failure were
also set to 0 as this information was also not collected at baseline. Data on the number of years since any
previous MI or stroke were collected in the ADDITION-Europe study and entered as appropriate into the
model. As revascularisation is not a component of the UKPDS-OM and only a single case of amputation
was reported during follow-up in the ADDITION-Europe study, only MI and stroke events were examined in
this analysis.
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Statistical analysis
We calculated the observed and predicted risk of non-fatal MI and non-fatal stroke by country and trial
group using the UKPDS-OM. We employed multiple imputation to deal with missing data90 using the
Markov chain Monte Carlo method and assuming an arbitrary missing pattern. A multivariate normal
distribution was used to impute missing values for age, sex, weight, height, smoking status, total cholesterol,
HDL cholesterol, systolic blood pressure and HbA1c. It has been previously demonstrated that multivariate
normal imputation is less biased than complete-case analysis91 and produces similar results to other
approaches despite the presence of binary and ordinal variables that do not follow a normal distribution.
If the imputed HDL cholesterol value was greater than the total cholesterol value (five cases at baseline; one
case at final follow-up), we assumed that HDL cholesterol (mmol/l)= total cholesterol – 0.1. For each patient
with missing data we undertook five imputations and computed the average of the five risk estimates.92
In the UKPDS-OM the categories of the variable ethnicity were white-Caucasian, Afro-Caribbean,
and Asian-Indian. In the ADDITION-Europe cohort there were some unknown or unclassifiable values,
for example mixed white+African, mixed white+Asian or others. These cases were unavoidably excluded
from the analysis as ethnicity is improper for multiple imputation (156 cases).
We examined the discrimination of the UKPDS-OM by computing the area under the receiver operating
characteristic (aROC) curve and assessed goodness of fit using the Hosmer–Lemeshow chi-square test.
The same methods have been employed in previous studies for the validation of the UKPDS and
Framingham risk engines.87,88,93
In the UKPDS-OM, both MI and stroke are assigned a particular Weibull regression equation with age, sex,
HbA1c and other variables as covariates.85 To examine which distribution was the best fit for baseline risk of
MI and stroke, we performed a number of survival regression analyses including exponential, log-normal,
log-logistic, Weibull and generalised gamma. We computed minimal Bayesian information criterion (BIC)
and Akaike information criterion (AIC) values to assess global model fit.94 We then analysed the covariates
with the best fit distribution to determine if they were significantly associated with MI and stroke. A p-value
of < 0.10 was defined as statistically significant.95 As risk factor values were not available for every year of
follow-up in the ADDITION-Europe trial cohort, the average of the baseline and final follow-up values
was used.
We also conducted a complete-case sensitivity analysis to examine whether or not the results were
replicated after excluding patients for whom there were missing data (n= 781/2899; 26.9%). Statistical
analyses were performed with SAS v9.3.
Results
Of the 3055 ADDITION-Europe participants, 156 were excluded as a result of unclassifiable or unknown
ethnicity. Baseline values for age, sex, treatment group and HbA1c did not differ significantly between the
included and excluded patients.
Observed and predicted risk of non-fatal myocardial infarction and stroke
The non-fatal MI and stroke rates for the ADDITION-Europe participants were 0.0228 and 0.0152,
respectively. The observed risks of MI and stroke were lower than the predicted risks using the UKPDS-OM.
When the data were broken down by country, overestimation was greater in the Dutch population than in
the Danish and UK populations for both non-fatal MI and non-fatal stroke (Table 6).
Examination of the absolute event rates between intervention groups represents the impact of IT
compared with RC. For non-fatal MI, the difference between intervention groups was higher than that
predicted by the UKPDS-OM, suggesting that the UKPDS-OM underestimated the effect of IT. For non-fatal
stroke, the difference was much smaller between the observed and predicted data, indicating only a slight
overestimation (see Table 6).
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Discrimination analysis
The aROC curve was 0.72 (95% CI 0.66 to 0.79) for non-fatal MI and 0.70 (95% CI 0.64 to 0.77) for
non-fatal stroke, suggesting that the UKPDS-OM had moderate discriminatory ability. The Netherlands had
the lowest aROC curve for MI (0.69) and the highest for stroke (0.79). Results from the Hosmer–Lemeshow
test were non-significant in the overall trial cohort and in each country, suggesting that the goodness of
fit was acceptable (Table 7).
Survival regression analysis
Following survival analysis, an exponential distribution was the best for baseline risk for both MI and stroke
based on BIC values. For AIC values, log-normal and exponential distributions provided the best fit for MI
and stroke, respectively. As such, we used the exponential distribution in survival regression analysis with a
selection of different covariates: age, sex, treatment group, smoking status, body mass index, HbA1c level,
systolic blood pressure and ln(total cholesterol/HDL) for MI or total cholesterol/HDL for stroke. Age, sex and
HbA1c level were significantly associated with non-fatal MI; age and sex were significantly associated with
non-fatal stroke (Table 8).
Complete-case analysis
In total, 2118 (out of 2899) participants were included in the complete-case analysis. Compared with
participants excluded because of missing data, the included participants had a slightly lower mean age
(60.09 vs. 60.84 years) and a higher mean HbA1c value (7.06% vs. 6.96%); there was also a higher
proportion of men (59.0% vs. 55.3%) among the included participants. The results were generally similar
to the results of the main imputed analysis in terms of observed and predicted risk and best fit distribution.
The one exception was for the survival analysis, for which sex no longer remained significantly associated
with stroke and HbA1c became significant.
TABLE 6 Observed and predicted risk of non-fatal MI and stroke by country and intervention group in the
ADDITION-Europe trial
Event Centre Intervention Total n
Number
of events
Observed risk
(95% CI) (%)
Average predicted
risk (%)
Non-fatal MI All RC 1314 39 2.97 (2.12 to 4.04) 6.86
IT 1585 27 1.70 (1.13 to 2.47) 6.77
Denmark RC 601 25 4.16 (2.71 to 6.08) 6.46
IT 851 14 1.65 (0.90 to 2.74) 6.16
The Netherlands RC 212 2 0.94 (0.11 to 3.37) 8.45
IT 236 2 0.85 (0.10 to 3.03) 8.74
UK RC 501 12 2.40 (1.24 to 4.15) 6.67
IT 498 11 2.21 (1.12 to 3.92) 6.87
Non-fatal
stroke
All RC 1314 19 1.45 (0.87 to 2.25) 2.30
IT 1585 25 1.58 (1.02 to 2.32) 2.34
Denmark RC 601 8 1.33 (0.58 to 2.61) 2.24
IT 851 12 1.41 (0.73 to 2.45) 2.05
The Netherlands RC 212 2 0.94 (0.11 to 3.37) 3.00
IT 236 2 0.85 (0.10 to 3.03) 3.63
UK RC 501 9 1.80 (0.82 to 3.38) 3.08
IT 498 11 2.21 (1.11 to 3.92) 2.21
Source: reproduced open access from Tao et al.96
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Cost-effectiveness analysis
In our second analysis we aimed to examine the short- and long-term cost-effectiveness of IT compared
with RC among people with screen-detected type 2 diabetes.
Methods
This analysis used data from the two UK centres (Cambridge and Leicester) in the ADDITION-Europe trial.
Costs
These included the cost of delivering the intervention and the routine cost to the NHS of treating
diabetes and diabetes-related events observed during trial follow-up. All costs were calculated in UK
pounds and monetary values were transformed to the 2009/10 UK national level using the Hospital and
Community Health Services Pay and Prices Index,97,98 which coincided with the census date for
outcome assessment.
TABLE 7 Discrimination and calibration analysis results for the UKPDS-OM using ADDITION-Europe trial cohort data
Event Centre aROC curve (95% CI)
Chi-square value from the
Hosmer–Lemeshow test
p-value from the
Hosmer–Lemeshow test
MI All centres 0.72 (0.66 to 0.79) 9.79 0.28
Denmark 0.76 (0.66 to 0.85) 7.61 0.47
The Netherlands 0.69 (0.45 to 0.94) 7.11 0.53
UK 0.70 (0.59 to 0.81) 8.01 0.43
Stroke All centres 0.70 (0.64 to 0.77) 9.10 0.33
Denmark 0.76 (0.68 to 0.84) 7.59 0.47
The Netherlands 0.79 (0.55 to 1.00) 7.17 0.52
UK 0.65 (0.54 to 0.76) 6.07 0.64
Source: reproduced open access from Tao et al.96
TABLE 8 Goodness of fit of baseline risk and covariates of survival regression analysis using ADDITION-Europe trial
cohort data
Event Distribution BIC AIC
Covariates significant (p> 0.10)
from the exponential distribution
MI Gamma 656.12 585.50 Age, sex, HbA1c
Exponential 641.45 583.43
Log-logistic 648.95 585.13
Log-normal 646.98 583.16
Weibull 649.24 585.43
Stroke Gamma 434.02 364.41 Age, sex
Exponential 418.54 360.50
Log-logistic 426.21 362.39
Log-normal 426.27 362.45
Weibull 426.21 362.40
Source: reproduced open access from Tao et al.96
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Cost of delivering the ADDITION intervention
The cost of delivering the intervention included the costs of (1) the design of the materials, and consultation
meetings with health professionals regarding development and production; (2) practitioner and patient
meetings, which included the costs of delivering the meetings, the time of consultants and educators and
the time of doctors and nurses; and (3) extra patient consultations and treatment (including prescription of
cardioprotective medication and glucometers with strips) (Table 9). The unit costs for the time of doctors,
nurses and other health professionals were obtained from standard UK unit cost references.97,98 The volume
of resources used was obtained from the ADDITION study protocol47 and relevant trial documents. Some
costs were estimated from internal accounting during the trial. The cost for extra prescriptions in the IT
group (compared with the RC group) was established in treatment algorithms in 2001 at the beginning of
the ADDITION study and was transformed to 2009/10 prices. Intervention costs were different in Cambridge
and Leicester and were averaged for the purposes of the cost-effectiveness analysis. For the long-term
analysis we assumed that the additional prescription costs in the intervention arm would continue to be
incurred each year.
Cost of the treatment of diabetes and diabetes-related complications
Unit treatment costs were obtained from published literature (Table 10). We collected the annual
treatment cost of type 2 diabetes without complications and type 2 diabetes-related complications in the
year of the event and in subsequent years. We extracted both inpatient costs (costs of admissions to
hospital either as a day case or as an inpatient for ≥ 1 night) and non-inpatient costs (costs of all home,
clinic and telephone contacts with GPs, nurses, podiatrists, opticians and dieticians and with eye and other
hospital outpatient clinics) from the UKPDS,100 from where the majority of treatment costs used in this
study were taken. In the short-term within-trial cost-effectiveness analysis and the long-term modelling
analysis we used an additive method to sum the annual costs of multiple complications.85
Utility decrement
We collected published utility decrement data to calculate quality-adjusted life-years (QALYs) as the health
outcome measurement for diabetes without complications and diabetes with complications, including
ischaemic heart disease, MI, heart failure, stroke, revascularisation, amputation, blindness and renal failure
(see Table 10).102 The majority of these utility data were taken from the UKPDS study based on EQ-5D
measurement.104 The same value was assigned to the year of the event and to subsequent years. For patients
with multiple events the additive method was used in which we summed utility decrements for each event.
Thus, the health state of patients diagnosed with diabetes with no complications was assigned a utility of
1 – 0.22= 0.78. Those with diabetes and a history of MI were assigned a value of 1 – 0.22 – 0.055= 0.725.
Utility decrements were applied until death; thus, a patient experiencing a MI would experience a 0.055
decrement to their utility in the year of the infarction and for every subsequent year.
Short-term cost-effectiveness analysis
We calculated the accumulated costs and QALYs for every year from diabetes diagnosis based on observed
events (MI, stroke, revascularisation and amputation) in the ADDITION trial. Both costs and QALYs incurred
after the first year were discounted at 3.5% per annum in line with current UK guidelines.105 To adjust for
baseline imbalances we used ordinary least squares regression analyses to calculate costs and QALYs as a
function of intervention group (RC/IT), treatment centre (Cambridge/Leicester), age at diagnosis, sex and
HbA1c level at baseline. Adjusted incremental treatment costs and QALYs were reported as means and
95% CIs.
Long-term modelling analysis
We used the UKPDS-OM (version 1.3) to perform long-term modelling analysis85 as it is derived from a UK
population and focuses on cardiovascular complications. Our validation analysis described earlier96
concluded that the model provided a reasonable prediction of the incremental event rate although it
tended to overestimate the absolute event rates.
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Information from ADDITION trial participants at baseline was entered into the UKPDS-OM, including age at
diagnosis, sex, ethnicity, duration of diabetes, weight, height, smoking status, systolic blood pressure,
HbA1c, total cholesterol, HDL cholesterol and years since pre-existing CVD events. Values for smoking
status, systolic blood pressure, HbA1c, total cholesterol and HDL cholesterol were also included from
measurements taken at 1 and 5 years’ follow-up. For the years in between (2, 3 and 4 years) and for
future years, the risk factor values were simulated by the UKPDS outcomes risk equations, that is, left to
propagate through the long-term model. Data on AF, PVD, ischaemic heart disease, congestive heart
failure, amputation, blindness and renal failure at diagnosis were not collected in the ADDITION study.
Given that all participants were newly diagnosed, all values were set to zero for these variables.
To deal with missing data, multiple imputation was applied using the Markov chain Monte Carlo method
assuming an arbitrary missing pattern.90,106 A multivariate normal distribution was used to impute missing
values of weight, height, smoking status, cholesterol, HDL cholesterol, systolic blood pressure and HbA1c.
In the UKPDS-OM the required ethnicity categories were white Caucasian, Afro-Caribbean and Asian-Indian.
There were some unknown or unclassifiable values, for example mixed white+African, mixed white+Asian,
etc., in the ADDITION-UK trial. It was not suitable to replace these using multiple imputation and so we
excluded these participants from the analysis (n= 25). After imputation, if the imputed HDL cholesterol value
was higher than the cholesterol value (which was logically impossible), we assumed that HDL cholesterol
(mmol/l)= cholesterol – 0.1 (five cases at baseline; one case at final follow-up). Five imputations were taken
for each participant and we combined the results with Rubin’s rules.90,92
Using the UKPDS-OM we performed a patient-level modelling analysis on time horizons of 10, 20 and
30 years with a discount rate of 3.5%. We report the 30-year simulation as the main result. For each time
horizon, 1000 inner loops and 100 bootstraps were conducted.107 Means and CIs at the patient level were
used to conduct a further bootstrap analysis, adjusting for centre, age at diagnosis, sex and HbA1c at
baseline as per the short-term analysis. Incremental cost-effectiveness ratios (ICERs) for the 10-, 20- and
30-year simulations are reported.
TABLE 10 Unit costs (2009/10 £) and utility decrements for diabetes and diabetes-related complications
Event
Cost, year of event (£) Cost,
subsequent
years (£) Source
Utility
decrement SourceFatal Non-fatal
Type 2 diabetes – 494.5 494.5 Clarke et al.100 –0.220 Schwarz et al.101
Ischaemic heart disease – 3558.4 1175.2 Clarke et al.100 –0.090 Clarke et al.102
MI 2295.6 6861.8 1129.8 Clarke et al.100 –0.055 Clarke et al.102
Heart failure 3968.4 3968.4 1391.1 Clarke et al.100 –0.108 Clarke et al.102
Stroke 5786.8 4196.9 793.4 Clarke et al.100 –0.164 Clarke et al.102
Revascularisation – 4943.1 316.3 Valentine et al.103 –0.059 Valentine et al.103
Amputation 13,664.2 13,664.2 788.7 Clarke et al.100 –0.280 Clarke et al.102
Blindness – 1791.7 758.9 Clarke et al.100 –0.074 Clarke et al.102
Renal failure 30,599.2 30,599.2 30,599.2 Schwarz et al.101 –0.263 Clarke et al.102
CVD death 3724.3 – – Valentine et al.103 –
Costs extracted from the UKPDS study were based on participant hospital records and a survey of 3488 UKPDS participants
in 1996–7 from which inpatient and outpatient costs were predicted. From this a representative cost per patient per year
was estimated for each complication/event. The cost estimates incorporate an expected length of stay in secondary care
and home, clinic and telephone contacts with GPs, nurses and allied health professionals.
Source: reproduced from Tao et al.,99 under the Creative Commons Attribution 4.0 International licence (CC BY 4.0).
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Analysis of uncertainty
Decision uncertainty is illustrated with a scatterplot of incremental cost–QALY pairs and the cost-effectiveness
acceptability curve.108 One-way sensitivity analyses were performed on treatment costs for events (±10%),
utility decrements (±10%) and the discount rate (0%, 5%) using the 30-year simulation data with the
results shown as a tornado diagram.109 We also explored two scenarios with intervention costs of £750
(three-quarters of the cost) and £500 (half of the cost) to represent lower set-up costs (e.g. making use of
previously designed materials).
Statistical analyses of within-trial data were performed using SAS v9.3. Analysis of long-term modelled
scenarios was conducted using the UKPDS model and Microsoft Excel® 2013 (Microsoft Corporation,
Redmond, WA, USA).
Results
Of 1026 participants in the ADDITION-UK study, two withdrew from the study and 25 were excluded from
the modelling analysis because of unknown or unclassifiable ethnicity. Thus, 1024 participants were included
in the short-term cost-effectiveness analysis and 999 were included in the long-term modelling analysis.
The total cost of delivering the IT intervention in ADDITION-UK was £502,974. This equates to £981 per
person (£339 for materials and preparatory meetings, £370 for extra patient consultations and £272 for
extra treatments) (see Table 9). The cost by centre was £90,379 (£1482 per person) in Leicester and
£412,595 (£913 per person) in Cambridge.
Short-term cost-effectiveness analysis
There were no differences in cumulative QALYs over any time horizon from 1 to 5 years (Table 11).
The cumulative incremental cost to the NHS (intervention cost and other expenditure incurred as a result
of cardiovascular complications) ranged from £285 over a 1-year time horizon to £935 over 5 years
(discounted at 3.5%). As IT was more costly and led to virtually no incremental health gains compared
with RC over the first 5 years, we estimate that IT of people with screen-detected diabetes is, on average,
not cost-effective in the short term.
Long-term cost-effectiveness analysis
Intensive treatment was associated with positive incremental QALYs in the long term (0.0465 by 30 years,
statistically significant at 20 years and beyond). The incremental cost of IT compared with RC at 10, 20 and
30 years also increased over time to £1745 at 30 years, yielding a point estimate ICER of £82,250 at
10 years, which fell to £35,000 at 20 years and rose slightly to £37,500 at 30 years (see Table 11).
The unadjusted results suggest a lower point estimate QALY gain in the IT arm, which is reversed once
adjustment is made for baseline differences. The result suggests that, although cost-effectiveness improves
over time, it is still above commonly accepted thresholds in the UK (defined as reaching an ICER of
£30,000 per QALY gained),105 even over a 30-year time horizon (Figure 14).
Analysis of uncertainty
Uncertainty and sensitivity analyses were performed on the predicted 30-year results. The cost-effectiveness
plane based on bootstrap sampling shows the scatterplot of cost and QALY pairs under the base case
(intervention cost of £981 per person) and two alternative scenarios with lower IT intervention costs
(Figure 15) (£750 and £500 per person). Under these scenarios, 30-year point estimate ICERs are £37,503,
£32,550 and £27,178. The cost at which the ICER falls to £30,000 is £631. If the intervention could be
delivered ≤ £631 per patient, it may be considered cost-effective.
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FIGURE 14 Broken line chart showing the simulated ICERs at 10, 20 and 30 years for the ADDITION-Europe
intervention. Source: reproduced from Tao et al.,99 under the Creative Commons Attribution 4.0 International
licence (CC BY 4.0).
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Under all three scenarios, the majority of points are in the north-east quadrant, suggesting that IT is nearly
always both more expensive and more effective (generates more QALYs) than RC, although the proportion
of the probability mass in the north-west quadrant suggests that there is greater uncertainty around
whether or not incremental QALYs are positive. The probability of cost-effectiveness according to the three
different treatment costs (£981, £750 and £500) is 51.1%, 60.9% and 70.4% at a £20,000 per QALY
gained threshold and 65.1%, 71.1% and 77.0% at a £30,000 per QALY gained threshold, respectively
(Figure 16).
One-way sensitivity analyses varying unit treatment costs, utility decrements and the discount rate showed
that the discount rate had the biggest impact on the ICER, with the impact of variations in utility
decrements and treatment costs being minimal (Figure 17).
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FIGURE 16 Cost-effectiveness acceptability curves showing the probability of IT being more cost-effective than RC
based on net benefit values from bootstrap samples using three different costs of delivering IT. The two dotted
lines show the cost-effectiveness acceptability thresholds of £20,000 and £30,000 per QALY. Source: reproduced
from Tao et al.,99 under the Creative Commons Attribution 4.0 International licence (CC BY 4.0).
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FIGURE 17 Tornado diagram showing the influence of changing different parameters that contribute to the ICER
in the long-term cost-effectiveness modelling analysis. The choice of discount rate has the greatest impact on the
ICER (lower discount rate, unit costs and utility decrements all associated with a higher point estimate ICER).
Source: reproduced from Tao et al.,99 under the Creative Commons Attribution 4.0 International licence (CC BY 4.0).
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Chapter 5 Discussion and conclusions
Change in treatment and risk factors
Results from the ADDITION-Europe trial show that screening for type 2 diabetes and early intensive
multifactorial treatment of individuals found to have screen-detected diabetes is feasible in primary care.
Screening identifies people with high levels of modifiable cardiovascular risk factors. The proportion of
participants prescribed one or more blood pressure-, lipid- and glucose-lowering drugs and aspirin
increased significantly from baseline to 5 years’ follow-up in both study groups. There were small
differences in treatment between groups at 5 years favouring the IT group.
In both the IT group and the RC group, intermediate outcomes such as blood pressure and cholesterol
improved considerably in the 5 years following diagnosis by screening; weight and glycaemia levels did not
increase. In terms of change from baseline, and absolute levels of risk factors at 5 years, our results
compare well with those of other trials in which patients were recruited at diabetes diagnosis and followed
for 6 years.110,111 However, the between-group differences observed at 1 year,49 which were clinically
significant, were not maintained at 5 years and differences were smaller than those achieved in similar
studies.29,110 It is possible that adherence to treatment targets were suboptimal in this pragmatic trial.
In three of the centres, the screening algorithm included the use of risk scores encompassing treatment for
high blood pressure as one of the variables to predict diabetes risk. This limited the achievable differences
in blood pressure levels between groups. Indeed, at baseline in the UKPDS, which began recruitment
20 years before the ADDITION-Europe study, 12% of patients were prescribed antihypertensive medication
and 0.3% were prescribed lipid-lowering medication. In the ADDITION-Europe study, at baseline, 45% of
patients were prescribed antihypertensive medication and 16% were prescribed lipid-lowering medication.
Our trial was undertaken during a time of improvements in the delivery of diabetes care in general
practice. This included the introduction of evidence-based guidelines in Denmark112 and the Netherlands113
and the Quality and Outcomes Framework for primary care in the UK.114 Again, these guidelines and
frameworks are likely to have reduced the achievable differences in treatment and risk factors
between groups.
Despite increasing age and duration of diabetes there was a significant decline in 10-year modelled CVD
risk in the 5 years following diagnosis in both the RC group [–5.0% (SD 12.2%)] and the IT group [–6.9%
(SD 9.0%)]. Within all four centres the modelled CVD risk was lower in the IT group than in the RC group
at 5 years. Comparable improvements in the CVD risk factors that drive modelled CVD risk have been
reported among newly diagnosed patients enrolled in lifestyle interventions over 12 months.54,115 Such
changes were also observed among clinically diagnosed diabetes patients in the UKPDS trial at 6 years of
follow-up.110
Cardiovascular outcomes and all-cause mortality
The intervention to promote intensive target-driven management of individuals with screen-detected
diabetes was associated with a non-statistically significant 17% relative reduction in the incidence of a
composite cardiovascular event end point over 5 years. For all components of the primary end point,
differences favoured the IT group. Differences were smallest for stroke and largest for MI. Cardiovascular
event rates began to diverge after 4 years of follow-up. We found no evidence of an increased risk of
adverse events including self-reported hypoglycaemia or mortality. The incidence of cardiovascular events
in the ADDITION-Europe study (8.5% in the RC group) was lower than expected and less than event rates
among newly diagnosed patients in the UKPDS (12.1%).110
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The combined mortality hazard ratio for the IT group compared with the RC group was 0.91 (95% CI 0.69
to 1.21). The heterogeneity in results between countries was not statistically significant. In the UK there
were significantly fewer deaths in the IT group. In Denmark there was a non-significant reduction in
cumulative risk in the RC group. The mortality rate (6.7% in the RC group) was also lower than expected.
In the Hoorn study116 the mortality rate was 25% over 10 years in screen-detected patients and in newly
diagnosed patients in Denmark111 the mortality rate was 33% over 7.4 years. The mortality rate in the
ADDITION-Europe trial was similar to that seen in the Danish general population (without diabetes) of the
same age between 1995 and 2006.117 As before, this is most likely because of the high quality of care that
was delivered to patients early in the course of the diabetes disease trajectory in both the RC group and
the IT group.
Microvascular outcomes
Trial results for microvascular outcomes were similar to those for the cardiovascular outcomes. At 5 years,
increases in prescribed treatment and improvements in cardiovascular risk factors were not associated with
significant reductions in microvascular events. Differences between study groups favoured the IT group,
with differences smallest for neuropathy and greatest for retinopathy. As for the CVD outcomes, the
frequency of microvascular complications at 5 years’ follow-up was lower than expected. It was also lower
than the reported frequencies among individuals with diabetes for a similar length of time.32 We concluded
that this was most likely because of the early detection of diabetes and the high-quality treatment that we
observed in both study groups.
In terms of the nephropathy outcomes, 18.5% of ADDITION-Europe participants had any albuminuria at
diagnosis.50 This figure is not directly comparable to the estimate of 7.2% of patients with microalbuminuria
at baseline in the UKPDS as a higher level of urinary albumin excretion was used to define microalbuminuria in
the UKPDS.32 The rate of progression of albuminuria in the ADDITION-Europe study, from 18.5% at baseline
to 23.5% (1% per year), was half that observed in the UKPDS, despite ADDITION-Europe participants
being older (mean age 60 years vs. 52 years in the UKPDS) and more likely to have high blood pressure at
diagnosis.32 Similarly, higher progression rates were reported in the VADT (Veterans Affairs Diabetes Trial),118
ACCORD119 and ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified
Release Controlled Evaluation)120 trials. However, these studies recruited older people who had
long-standing diabetes.
We observed a beneficial increase in eGFR in both the IT group and the RC group. This is probably linked to
the treatment of multiple cardiovascular risk factors, including lipid-lowering treatment, glucose-lowering
treatment and ACE or ARB treatment.
As with the nephropathy outcomes, retinopathy frequency was lower than expected. Just 12%
of ADDITION-Europe RC patients developed retinopathy after 5 years of follow-up. In the UKPDS, 37% of
patients had retinopathy at diagnosis and a further 22% developed the condition during the next 6 years.31
Again, this is likely to reflect early treatment in the lead time between screen detection and clinical diagnosis.
A similar trend was observed for neuropathy, with 5% of the population reporting peripheral neuropathy
at 5 years, with no difference between groups. This is markedly lower than the 11% reported in a
population with an average diabetes duration of 16 years.67 However, caution should be exercised in
the interpretation of this result. We used the Michigan neuropathy questionnaire, which may not be
sufficiently sensitive121 or reliable to detect early progress of neuropathy and/or differences between the IT
group and the RC group.122 There was heterogeneity in the effect size estimates for peripheral neuropathy
across all centres, which supports this view.
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Patient-reported outcomes
Compared with RC, IT was not associated with differences in any PROMs (health status, well-being, quality
of life and treatment satisfaction) after 5 years of follow-up. Health status, as measured by the EQ-5D,
did not change between diagnosis and follow-up. Again, we conclude that the time period within which
our trial was undertaken, for example when targets for cholesterol and blood pressure became stricter for
diabetes patients, resulted in smaller than expected differences between study groups.
Baseline health-related quality of life was high in our cohort (median EQ-5D score of 0.85). EQ-5D estimates
remained stable over follow-up in spite of participants’ age increasing by 5 years. This is an important
finding, particularly as the burden of treatment increased over this time. In a study among 1136 Dutch
people with type 2 diabetes (mean age 64.9 years), the average EQ-5D score was 0.74 (SD 0.27).123 Older
patients, women and those with a longer duration of diabetes reported lower levels of health-related quality
of life. In a cluster-randomised trial in 55 Dutch general practices, there was no change in diabetes-related
health over 1 year between standard and intensive multifactorial therapy, although a negative effect on the
SF-36 social functioning score could not be ruled out.124 In the UKPDS, intensively treating blood pressure
and blood glucose in newly diagnosed diabetes patients did not adversely affect health status.39 In an
ACCORD substudy, there was a difference in change in the SF-36 physical component score and the DTSQ
scale over 4 years between the standard group and the intensive glucose-lowering group.40 However, the
absolute difference in the SF-36 score was only 0.5 units, considerably less than the general threshold of
3–5 points recognised as an important difference. ACCORD participants differed from ADDITION-Europe
patients in that they were older, they had had clinically diagnosed diabetes for an average duration of
9–10 years, 35% were on insulin treatment and they had a different ethnic background. Overall, the
findings from other studies are largely in line with the results from the ADDITION-Europe trial, that is,
no significant differences in PROMs between treatment groups.
It is worth noting that, although pooled analyses from all centres showed no differences between the
treatment groups, for some PROMs the results in Leicester clearly favoured the IT group. This might be linked
to the nature of the intervention. This was delivered by an intermediate care team at a community-based
diabetes specialist care facility. Patients also received weight management advice, a glucometer at diagnosis
and the DESMOND structured education programme.53 Other ADDITION-Europe centres relied on existing
primary care teams to achieve the IT targets.
Validation of the UK Prospective Diabetes Study
outcomes model
The UKPDS-OM had moderate discriminatory ability to predict non-fatal MI and stroke among
ADDITION-Europe participants. However, the model overestimated absolute risk. As diabetes patients begin
to be diagnosed earlier in the disease trajectory, and their CVD risk is therefore lower, the UKPDS-OM
may need updating for CVD risk prediction in contemporary diabetes populations.
The accuracy of the UKPDS-OM (version 1.3) in estimating the risk of non-fatal MI and stroke varied
between countries. It performed particularly poorly in the Netherlands compared with the UK and
Denmark. This could be because of a difference in baseline characteristics between the ADDITION-Europe
cohorts and the UKPDS cohort. The UKPDS population had some baseline characteristics associated with a
lower risk of CVD, including lower mean age, mean body mass index and mean systolic blood pressure,
and some characteristics associated with a higher risk, for example a higher percentage of men, a lower
mean HDL cholesterol level and a slightly higher mean HbA1c level. The UKPDS also excluded people with
previous CVD. However, the purpose of the UKPDS-OM is to provide coefficients for the inputted risk
factors. As such, the accuracy of the predicted risk should be relatively insensitive to the baseline
characteristics. We could reject a model on the basis of baseline characteristics only if the two populations
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were very different, for example predicting the risk of CVD based on a cohort of individuals aged 80 years
and applying these risks to a cohort of individuals aged 20 years.
The most likely reason for the overestimation of risk is because of improvements in treatment between the
time that the UKPDS data were collected (1977–97) and the time of ADDITION-Europe data collection
(2002–6). The ADDITION-Europe intervention also included a much more comprehensive set of preventative
treatments offered from an earlier stage in the disease. Our results are consistent with those of other
studies examining the predictive ability of the UKPDS and Framingham models in populations with lower
disease rates.88,125
As AF and PVD data were not collected at baseline, these variables were set to zero in the UKPDS-OM.
PVD was a risk factor only for amputation in the UKPDS-OM and so the omission of these data should not
affect our results. AF is a risk factor for stroke in the UKPDS-OM;85 missing data for this variable are likely
to underestimate stroke risk. However, in one study the prevalence of AF ranged from 1.2% to 2.8%
among people aged 60 years126 and so missing data for this variable are unlikely to have a large effect on
our results.
The UKPDS-OM performed differently in predicting the differences in CVD risk factors between the
intervention groups. It underestimated the incremental risk of MI between groups and slightly overestimated
differences for stroke. Assessment of the cost-effectiveness of health-care interventions necessitates
knowledge of the increment between the comparator groups, rather than the difference in absolute levels
of each group. It is ultimately a subjective decision whether or not these differences are sufficient to render
the UKPDS-OM unsuitable for extrapolating the ADDITION-Europe data. The insight from our work shows
that, if the UKPDS-OM is unadjusted, it will underestimate any reductions in MI risk attributable to IT and
consequently potentially underestimate the cost-effectiveness of the intensive intervention (i.e. overestimate
the ICER). The small disparity in the predicted compared with observed risk of stroke may be of limited
consequence because of the effects of discounting.
As stated above, the UKPDS-OM had moderate discriminatory ability for predicting non-fatal MI and
stroke. The aROC curve ranged from 0.65 to 0.79 and goodness of fit was acceptable. The UKPDS-OM
is based on a set of Weibull survival regression equations. For the model to perform successfully, it is
important to choose a suitable baseline distribution and relevant covariates. The best-fit model for the
ADDITION-Europe data was an exponential distribution. Our analyses showed that age, sex and HbA1c level
were important covariates and should be included in the UKPDS-OM.
Cost-effectiveness results
Cumulative costs and QALYs over a time horizon of 1–5 years indicated that IT was not cost-effective over
the short term. This result may be linked to the improvements in cardiovascular risk factors that were
observed in both trial groups between baseline and follow-up.55 In the long-term modelling analysis,
the 30-year simulated ICER was greater than the recommended UK National Institute for Health and Care
Excellence threshold (£20,000–30,000 per QALY),105 suggesting that interventions to promote delivery of
intensive multifactorial treatment in the ADDITION-UK study were not cost-effective compared with RC in
the long term.
The intervention becomes cost-effective only if it can be delivered at a cost of < £631 per participant.
The cost of delivering IT in our analysis (£981 per participant) was calculated based on the study protocol,47
which covered all aspects of the intervention. This figure may overestimate the cost of reproducing the
intervention as trial materials would not require complete redevelopment (although some adaptation to
local needs would be likely). Alternative approaches to influencing practitioner behaviour, such as
point-of-care reminders and decision aids, might be cheaper than practice visits by specialists. Furthermore,
treatment costs were based on payments made to GP practices according to predicted costs based on the
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study protocol rather than actual costs. These costs may have been overestimated as GPs prescribed less
medication than expected.55 Finally, as per our validation analysis, the UKPDS tends to overestimate the
risks of cardiovascular events, which could have led to overestimation of the ICER.
Our finding of a general improvement in cost-effectiveness over the long term is exemplary of the nature
of preventative treatments. As most of the costs of such interventions are borne ‘up front’, and chronic
disease complications take a long time to develop, health and cost benefits are usually seen only over the
longer term. We used a 30-year modelling horizon in our analyses as the average age of participants at
baseline was 60 years. We therefore assumed that a 30-year time horizon would equate to a lifetime
horizon for the majority of individuals. A key question for policy-makers is whether or not they are
prepared to consider a lifetime horizon in their decision-making. The optimal time horizon for any
economic evaluation is one that is sufficient to capture all impacts on incremental costs and outcomes.127
In our case, this suggests a lifetime horizon. However, investing in an intervention now means spending
the money from this year’s budget without seeing any benefit for many years. During this time personnel,
governments and government policy may change. Introducing such polices is therefore a challenge given
pressures (political or otherwise) to show the benefits from investment decisions over the short to
medium term.
The DESMOND study examined the benefits of a structured education and self-management programme
for people with newly diagnosed diabetes in the UK from 2004 to 2006.53,128 The authors found that the
intervention was likely to be cost-effective compared with usual care over a lifetime horizon (ICER £5387).
One reason for the difference between our results and the results of the DESMOND study and other
studies might be the early disease stage of participants in our study. Early detection might help prevent
complications in the future by attenuating disease progression. However, intervening ‘too early’ might be
less cost-effective. For example, intervening when an individual presents with diabetes-related symptoms
may reduce the risk of an event that would otherwise have occurred in 5 years’ time. Intervening at an
earlier stage, after detection of IGT, for example, may prevent an event that would not otherwise occur for
20 years. In general, individuals and society have a preference for benefits now rather than in the future.
As such, they would value preventing an event in the next 5 years more highly than preventing the same
event in 20 years’ time.
Strengths and limitations
The ADDITION-Europe study participants were drawn from representative population-based samples in
three different European countries. Practices were recruited from a large geographical area in each
country. Randomised practices (26% of those invited) were nationally representative in terms of key clinical
and sociodemographic characteristics.43,48,49 However, recruitment was non-random and the generalisability
of our findings to other settings should be considered with caution. Furthermore, participants were
predominantly white (93%), which might limit the extrapolation of our data to more ethnically diverse
regions. Individuals were identified using a range of different screening programmes and were diagnosed
according to 1999 WHO criteria.56
The study intervention included algorithms and targets based on well-established trial data and we used a
range of methods associated with changes in practitioner and patient behaviour. We randomised general
practices rather than individuals (as the intervention was delivered mainly by practitioners) to minimise the
risk of contamination. We achieved high levels of participant retention and independently adjudicated
end-point ascertainment in both trial groups (99.9%). Trained staff were unaware of study group
allocation. We assessed clinically important outcomes using standardised equipment and protocols. For the
modelled CVD risk analysis, we used the latest version of the UKPDS risk score (version 3). This was derived
from > 40,000 patient-years of data and 1115 CVD events.75 For PROMs we used both generic and
diabetes-specific measures.
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There was variation between centres in the approaches to population-based screening for diabetes.
However, all participants were diagnosed according to WHO guidelines.56 Furthermore, the differences in
screening programmes do not affect the internal validity of the study as they apply equally to both study
groups in each centre. Rather, they increase the external validity or generalisability of the trial by including
patients detected using a range of different screening programmes. There was also variation in the
methods used to encourage the general practice teams to follow the treatment algorithms. However, there
was one common set of treatment targets and algorithms for the IT group in all centres and, as stated
above, this heterogeneity should increase generalisability without diminishing internal validity. We pooled
centre-specific estimates using fixed-effects meta-analysis and formally tested for heterogeneity between
centres using the I2-statistic. Although we acknowledge that this test has limited power, the primary
outcome and all of its components did not exhibit significant between-centre heterogeneity and so we
have not formally explored in this report explanations for any observed heterogeneity. Furthermore,
there are a number of other centre-level covariates other than those previously mentioned relating to
the different health systems in each country that may have contributed to variation in participant
characteristics and response to the intervention. The different approaches taken in each centre to promote
IT of multiple risk factors represent complex interventions. As the study was pragmatic, it is not possible to
determine which aspects of the interventions might have been effective and which aspects might have
been less so.
Cluster randomisation occurred before screening and patient recruitment. This design feature can
introduce a difference between groups in participant characteristics. Although individuals in the IT and RC
groups were well matched overall, in Denmark the intervention may have influenced the number and type
of patients recruited to the IT group. Staff undertaking opportunistic screening may have conducted more
tests in individuals at high CVD risk as they were aware of the potential benefits of early detection and
treatment. This may have attenuated the effects of the intervention and might explain some of the
differences in results between centres. Differences appeared to be present but might not have been
statistically significant because of the limited power of the test of heterogeneity. Our intracluster
correlation coefficients were small55 and did not adversely affect study power. Methods of screening,
laboratory testing and outcome assessment were standardised across study groups in each centre in this
pragmatic trial but did differ between centres. This may also have contributed to some of the observed
heterogeneity. Measurement of biochemical outcomes differed slightly between baseline and follow-up in
two centres but not between groups. Reassuringly, interlaboratory validation suggested that methods were
consistent between centres. Primary end points were adjudicated using a standardised manual and case
report form in each centre. Other potential sources of heterogeneity in our trial arise from variation
between centres in participant characteristics. This might be because of differences in the screening
programmes and underlying populations, different modes of delivering the intervention and other
unmeasured factors.
For the CVD outcomes analyses there were few differences between those with and those without
follow-up data. For the modelled CVD risk analysis, 27% of data were missing. Sensitivity analyses
suggested that the primary analysis was likely to represent an accurate ITT analysis. We accounted for
missing data at baseline using the missing indicator method and assumed that those lost to follow-up had
a 10% higher risk than those with available data at 5 years. There was qualitatively no change to the final
results and the difference in modelled CVD risk between groups remained significant. It is likely that we
overestimated the level of modelled CVD risk in our contemporary trial cohort as the UKPDS model is
based on a historical cohort diagnosed 20 years before the ADDITION-Europe study participants. However,
this would not have affected the effect size estimate differentially by group. There was no difference
between self-reported AF at 5 years between the RC group (13.3%) and the IT group (14.0%), suggesting
that the exclusion of this variable from the UKPDS model was unlikely to affect our findings.
For the microvascular outcomes analysis there were differences in the proportions of individuals with data
for different outcomes at 5 years. For example, 77% had retinopathy data and 95% had eGFR data. There
was some evidence of healthy volunteer bias when examining the characteristics of participants with and
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without microvascular outcome data; however, absolute differences were small [e.g. 0.19% (2mmol/mol)
for HbA1c]. There were no differences between the IT group and the RC group in terms of the proportion
with missing microvascular data. However, the prevalence of retinopathy and neuropathy might have been
underestimated considering the adverse risk profile of individuals with missing data for these outcomes.
Microvascular outcome assessment and laboratory testing were standardised across participants from the
IT and RC groups in each centre but did differ between centres; for example, there was no standardised
procedure for retinal photography. Some centres used routine secondary data sources, whereas others
collected retinal data during remeasurement of participants at the 5-year follow-up examination. This
variation might have led to differences in the precision of outcome assessment between centres but
not between study groups. Furthermore, we assessed only gradable photos and they were coded
using a standard scale (ETDRS65) by three experienced ophthalmologists who were unaware of study
group allocation.
For the PROMs, patients who completed the questionnaires differed from those who did not. However,
we believe that these differences are unlikely to have had an important effect on the outcomes as the
differences were small, were not in one direction and were similar for both the IT group and the RC group.
Our multiple imputation analysis confirmed the results of the main analysis, which supports our conjecture
that selective dropout of patients did not introduce significant bias. As most of the PROMs were not
measured at baseline, we were not able to examine changes in PROMs over time, nor adjust for baseline
measurement of each PROM. This would not have been possible for diabetes-specific outcome measures
such as the DTSQ and ADDQoL. We adjusted for a number of possible confounding variables, which were
similar between the IT group and the RC group at baseline. We also adjusted all models for the baseline
EQ-5D score as a proxy for baseline health status.
For the UKPDS-OM validation work we used multiple imputation, which allows the best use of the
available data and takes into account the uncertainty in missing values. Both the imputed data set and the
complete-case data set produced similar results, confirming the robustness of our results. Our validation
work was limited by a lack of annual CVD risk factor measurement. In the UKPDS cohort, biochemical data
were collected every year. We had to average baseline and follow-up values for the year of event in
regression analyses as they were not available for every year. We did not have information on baseline AF,
PVD, years since pre-existing CVD, blindness and renal failure. This might have introduced some
bias in model prediction and influenced the efficiency of the model, most likely contributing to an
underestimation of risk of CVD. We validated the UKPDS-OM using 5-year data and extrapolated the
model to a longer time horizon in our cost-effectiveness work to estimate the 30-year incremental
cost-effectiveness of the IT intervention. As follow-up continues more events will occur. We will revise our
estimate of the cost-effectiveness of the intervention once longer-term data are available.
For the cost-effectiveness work we examined outcomes over both the short term and the long term and
performed sensitivity analyses to test the robustness of our findings. We used data from the UKPDS, a UK
study of individuals with diabetes and long-term CVD outcomes to calculate unit costs, utility decrements
and modelled CVD risk. We adjusted for centre (Cambridge/Leicester) rather than practice as the
intervention differed slightly between the centres; however, within the same centre practices shared
standardised practitioner guidelines. Intraclass correlation coefficient values for GP practice for the primary
outcome were very small in the main ADDITION-Europe trial, supporting our decision to adjust for centre
rather than practice.
There were some limitations. First, we focused on only macrovascular outcomes (CVD and associated acute
events). Microvascular outcomes such as retinopathy and nephropathy are also important in assessing the
impact of type 2 diabetes on both quality of life and costs. Exclusion of these is likely to underestimate
the benefit from any preventative intervention and thus underestimate cost-effectiveness (i.e. overestimate
the ICER), particularly in the longer term as patients avoid CVD and live with diabetes long enough to
develop microvascular complications.
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Second, although the treatment protocol was identical, the lifestyle intervention was different in Leicester
and Cambridge. To represent the cost of implementing an ‘ADDITION-like’ intervention that reflected a
degree of diversity across the country we simply averaged the costs of the two interventions. We did,
however, include centre in the adjusted analyses estimating incremental costs and QALYs. Results were
similar when we adjusted for cluster (GP practice) and when running analyses separately by centre.
Third, we used an additive method to calculate treatment costs and utility decrements for individuals with
multiple events. This is a commonly used method and was applied in the UKPDS-OM,100,129 but it is unclear
if the cost and utility decrements of subsequent complications should be additive or multiplicative. A
review of health state utilities in patients with type 2 diabetes published after completion of our analysis130
recommends the use of the Clarke data set for most comorbid events, or health state utilities very close to
those used in our analysis, with one notable exception: we assigned a disutility of 0.263 for renal failure,
whereas Beaudet et al.130 recommend values between 0.204 and 0.164. Using a higher disutility will
overestimate the health gain from averting renal failure. However, we estimated the difference in risk of
renal failure over 30 years between the IT group and the RC group to be –0.05% (SE 0.06%). The impact
of this on the incremental QALY gain per patient in each arm is therefore likely to be negligible.
Fourth, most of the equations in the UKPDS-OM predict future risk factors and events based on baseline
values, time since diagnosis and the value of biometrics such as HbA1c level in the previous time period
(year). It is an individual-level model in which patient data are calculated individually (rather than as mean
values of a cohort). Thus, the model assumes that any trends present at 5 years will continue into the future,
effectively assuming a continuation of the effect of the small differences in treatment generated by the
intervention at 5 years. The 10-year follow-up of the UKPDS cohort found that, although between-group
differences in HbA1c level and blood pressure were both lost within 12 months of the end of the active
phase of the study, those who had previously achieved tighter control over HbA1c still had a lower event rate
at 10 years than those who had not, while any benefit from lower blood pressure was not maintained.131,132
Current guidelines and practice have changed since the initiation of the ADDITION-Europe trial, with
patients recommended to receive at least as IT as the ‘intensive’ arm. Trial patients in the RC arm received
a higher level of treatment than observed in ‘standard practice’, which may have diluted the observed
incremental health gain. However, after 5 years of treatment, there was room for improvement in the
prescription of cardioprotective treatment in both groups. Current evidence suggests that delays in
treatment intensification in people with type 2 diabetes (clinical inertia) are still very common.
On the cost side, the official duration of the IT intervention was 3 years, for which practices were
reimbursed for additional activity and prescriptions. We projected additional prescribed drug costs in the IT
arm over the full 30 years under the assumption that patients in the RC arm would not increase their
medication and patients in the IT arm would not decrease their medication over time. We may, therefore,
have overestimated the cost of the IT arm. Whether this is true or not will be assessed once the 10-year
follow-up data from the ADDITION-Europe cohort are available for analysis.
Finally, although we used the most appropriate CVD risk model available, as outlined earlier, the UKPDS-OM
was derived using data from a historical cohort of people with clinically diagnosed diabetes. The ADDITION
cohort included people with screen-detected diabetes. Other research125,133 has shown that the UKPDS-OM
tends to overestimate absolute CVD risk, a finding replicated in our own investigation of the suitability of the
UKPDS-OM to extrapolate ADDITION study data.96 Furthermore, the utility decrements for MI and stroke
derived from the ADDITION study were smaller than those in the UKPDS, a finding that is consistent with
contemporary patients receiving better care and hence reporting higher quality of life. This underlines the
importance of our sensitivity analyses, which showed that changes to these parameters did not substantially
affect the ICER. Of the discount rate, intervention unit cost and utility decrement, variations in the discount
rate had the biggest impact on the ICER.
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Conclusion
Improvements in the quality of diabetes care in general practice during the duration of the
ADDITION-Europe trial meant that treatment in the RC group was better than expected and not very
different from the care provided in the IT group.55 Cardiovascular risk factors (weight, blood pressure,
cholesterol and modelled CVD risk82), including health-related behaviours (smoking), improved substantially
following detection of diabetes by screening, even among those receiving RC. The small differences
between groups in the intensity of treatment during the 5 years following diagnosis were associated with
a non-significant 17% reduction in the primary composite cardiovascular end point in favour of the IT
group.55 There was no difference between the groups at 5 years in the prevalence of microvascular
outcomes83 or in health status, well-being, quality of life or treatment satisfaction.84 Recent trials of IT of
glycaemia among patients with long-standing diabetes suggest that adverse effects occur early35,134 and
that any benefit in terms of a reduction in cardiovascular risk takes longer than 5 years to be realised.131
Whether or not the small difference in the intensity of treatment of multiple CVD risk factors early in the
course of the disease in the ADDITION-Europe study will translate into a significant reduction in
cardiovascular events and mortality over the longer term is uncertain.
We demonstrated that it was feasible to use the UKPDS-OM model to extrapolate the ADDITION-Europe
data.96 We took account of the possible underestimation of any reductions in MI and used the model in
our cost-effectiveness analysis. Cost-effectiveness work showed that promotion of IT compared with RC
was not cost-effective over a short- to medium-term time horizon for people with screen-detected diabetes
in the UK. However, the intervention has the potential to be cost-effective if it can be delivered for
approximately £630 per patient rather than £981. Such savings may be plausible through adaptation of
predeveloped materials and economies of scale in delivery. Although there were few differences between
screened and unscreened populations, the small proportion (2.9%) of individuals whose diabetes was
detected by screening did appear to benefit.23
Implications for clinical practice
The ADDITION-Europe randomised trial did not deliver conclusive evidence to justify implementation of a
systematic screening and early treatment programme. Uncertainties remain, particularly concerning the
overall cost-effectiveness of screening and early treatment for undiagnosed diabetes. However, the overall
results of the ADDITION-Europe study suggest that earlier detection and treatment of diabetes is
associated with net benefits. Although it remains uncertain whether or not IT is associated with a
reduction in CVD or microvascular end points over the long term, there was no evidence that IT adversely
affects PROMs early in the course of the disease. Furthermore, despite increases in age and diabetes
duration, modelled CVD risk estimates decreased in the whole trial cohort from baseline to follow-up.
Our research suggests that practitioners can safely treat multiple cardiovascular risk factors early and
intensively in the diabetes disease trajectory when the rate of CVD risk progression may be slowed.
The observed absolute and relative risks of cardiovascular events and mortality among participants with an
average HbA1c level of around 6.5% 5 years after diagnosis should reassure practitioners concerned about
IT for hyperglycaemia. There was no interaction between IT and age or previous history of cardiovascular
events, although there was a suggestion that benefits associated with IT were greatest among participants
aged ≥ 60 years at diagnosis. Multifactorial treatment of screen-detected patients in both study groups
was associated with improvements in cardiovascular risk factors and lower than expected rates of
cardiovascular events and mortality.
In summary, primary care teams might consider the benefits of earlier detection (albeit not necessarily
through population-based screening), lifestyle advice and IT for risk factors among those at high risk of
diabetes and high risk of CVD. This might include opportunistic screening among those known to be at
highest risk, based either on routinely available information such as age, body mass index and the presence
of related conditions such as hypertension or on risk questionnaires/scores. Individuals identified in this way
might be offered lifestyle interventions and preventative drug treatment appropriate to their level of risk.
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Future research recommendations
Future research might focus on ways to increase the yield of programmes for the earlier detection of
diabetes and assessment of cardiovascular risk. There is also a need to examine and implement effective
and cost-effective care pathways for individuals who screen negative but who are at high risk of diabetes
and CVD. The ADDITION-Europe study focused on the treatment of people with screen-detected diabetes,
but the screening programme in each centre identified many more individuals without diabetes but
who were at high risk of developing diabetes and CVD. In Denmark, for each person found with
screen-detected diabetes, two people at high risk of developing diabetes and a further six people without
diabetes but fulfilling guideline indications for preventative treatment of high risk factors for CVD were
identified. Most of these people were not treated optimally according to current guidelines.50,135 There is
clearly an efficiency to combining strategies to identify individuals at high risk of both diabetes and CVD.
Future research should also examine ways to intensify treatment and adherence. There was evidence of
suboptimal treatment in this pragmatic trial.55
Finally, future research should focus on whether or not the slowing of CVD risk progression observed in
ADDITION-Europe trial participants in the first 5 years following diagnosis82 leads to a sustained reduction
in CVD events over the long term. Outcomes tended to favour the IT group among ADDITION-Europe
participants; however, the low frequency of events means that the 5-year duration of follow-up may have
been insufficient to detect potentially clinically important differences between the RC group and the IT
group. The apparent divergence of event rates from 4 years also suggests that further follow-up of the
ADDITION-Europe trial is justified to examine whether early intensive multifactorial treatment reduces
cardiovascular risk in the long term as seen in the UKPDS.131 Longer-term follow-up of the ADDITION-Europe
trial cohort alongside examination of microvascular, quality of life and cost data is therefore needed to
establish the cost-effectiveness of IT among screen-detected patients.
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Appendix 1 Further details of the intervention in
each study centre
The intervention in ADDITION  
Description of the centre specific intervention in the intensive arm 
 
June  - Sept 2006 
Updated Sept 2007 and May 2010 
 
In overall  
. 
• 
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Treatment guidelines:  
 
 
• o 
o
o 
• 
• 
• 
• 
Giv patienterne tilbud om fuld risikoreduktion:
Forslag til behandling – se modsat side!
Er du i tvivl: RING 89 42 60 52
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Treatment targets 
 
HbA1c < 7%* 
Blood pressure < 130/80 mmHg 
Cholesterol < 3.5 mmol/l 
Annual consultation schedule 
 
1 hr Specialist Care Team appointments – diagnosis and 2 months 
(including 
retinal screen and complications check) 
30 minute Specialist Care Team appointments – 4, 6, 8 and 10 months   
15 minute Diabetes specialist nurse appointments – 2 weeks and 4 weeks 
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1hr annual review (including complications check) with Specialist Care 
Team – 
12 months 
Plus any further interim contact required or requested by the patients 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
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